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Ultrasmall (<2 nm) noble metal nanoclusters (NCs), particularly Au and Ag 
NCs, have been an attractive frontier of nanoparticle research because of their 
unique physicochemical properties such as well-defined molecular structure, 
discrete electronic transitions, quantized charging, and strong luminescence. 
The unique properties of Au/Ag NCs in combination with their ultrasmall size 
and good biocompatibility have enabled them as emerging functional materials 
for a variety of biomedical applications, especially those for in vivo settings. 
The bio-integrated synthesis is a great approach to synthesizing noble NCs for 
biomedical application as it is able to integrate the requirements and 
considerations of the specific biomedical application into the design of the 
synthetic process so that the resultant noble metal NCs can be inherently better 
suited for the particular biomedical applications. 
In this thesis project, we explored the bio-integrated synthesis of thiolated 
Au NCs for application in radiotherapy sensitization as a model system. We first 
identified the general design criteria for noble metal NCs for biomedical 
applications and determined to synthesize biocompatible and renal clearable 
noble metal NCs. In addition, synthesis methods for highly luminescent 
thiolated Au NCs with a wide size range are essential for developing bio-
integrated synthesis of thiolated Au NCs as ideal radiosensitizers. Thus, we 
focused on the fundamental understanding of the photoluminescence properties 
and the growth mechanisms of the thiolated Au NCs. On the basis such 
understanding, we designed efficient synthetic approaches for highly 
luminescent thiolated Au NCs and highly monodisperse water-soluble ~2 nm 
thiolated Au nanocrystals. Last, we applied an ultrasmall biothiol-protected Au 
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NCs from bio-integrated synthesis for in vivo cancer radiotherapy sensitization 
to understand their in vivo behaviors and radiosensitizing efficacy. 
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CHAPTER 1    
INTRODUCTION 
1.1 Bio-integrated synthesis of noble metal nanoclusters for 
biomedical applications 
Noble metal nanoclusters (NCs) are ultrasmall particles that have core sizes 
smaller than 2 nm.1-3 In recent years, the research in noble metal NCs, 
particularly Au/Ag NCs, has emerged as a dynamic and promising frontier in 
the nanoparticle community. Invariably, the interest in such sub-2 nm Au/Ag 
NCs is fueled by their unique and intriguing physical and chemical properties, 
such as well-defined molecular structure,4-10 discrete electronic transitions,11, 12 
quantized charging,13, 14 magnetism,15 optical chirality,6, 7, 9, 16 and strong 
photoluminescence,17-19 which are not seen in the corresponding bulk materials 
or nanomaterials with core sizes above 2 nm. The properties of Au/Ag NCs are 
highly sensitive to their size, surface, and structure, which provide invaluable 
means to tailor the NC properties for applications in catalysis, medicine, and the 
environment. In particular, the unique properties of Au/Ag NCs in combination 
with their ultrasmall size and good biocompatibility have enabled them as 
emerging functional materials for a variety of biomedical applications, 
especially those for in vivo settings. For example, the strong photoluminescence 
of Au/Ag NCs has been used to develop optical probes for biosensing, 
biolabeling, and bioimaging applications.3, 18-23 The Ag NCs, in particular, also 
showed unique antimicrobial properties with a high bactericidal efficacy, even 
superior to the well-commercialized Ag-based antimicrobial agents, which are 
typically large Ag nanoparticles (NPs) with core sizes above 2 nm.24 
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As features of noble metal NCs that are required may vary for different 
biomedical applications, it is essential that the properties of the noble metal NCs 
can be controlled according to the requirements of the targeted biomedical 
applications. This issue can be well addressed by employing bio-integrated 
synthesis of the noble metal NCs. By definition, the bio-integrated synthesis is 
able to integrate the requirements and considerations of the specific biomedical 
application into the design of the synthetic process so that the resultant noble 
metal NCs can be inherently better suited for the particular biomedical 
applications. The ideal bio-integrated synthesis should produce noble metal 
NCs that are benign to biological systems. For example, for in vivo applications, 
the noble metal NCs should be biocompatible and renal clearable, which could 
be achieved by using biocompatible noble metals (e.g., Au) as the core materials 
and biomolecules as the ligands and controlling the hydrodynamic diameter to 
be less than the threshold of kidney filtration (~5.5 nm).25  The noble metal NCs 
produced by ideal bio-integrated synthesis should also have the desired 
physicochemical properties for the specific biomedical application. For 
instance, for in vivo bioimaging application, the NCs should have bright 
luminescence in the red to near-IR regime, which can effectively penetrate 
tissues. In addition, the bio-integrated synthesis should also be “green”, so that 
the process is efficient even for large-scale synthesis and the product is 
inherently safe. For example, the synthetic process should consist of few and 
simple steps, using ambient and aqueous conditions, and using few non-toxic 
auxiliary reactants.  
In this thesis project, we chose to explore the bio-integrated synthesis of 
noble metal NCs for a model biomedical application: radiosensitizers for cancer 
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radiotherapy. Cancer remains one of the world’s most devastating diseases with 
more than 10 million new cases each year, and radiotherapy is a leading cancer 
treatment approach that addresses the needs of more than 50% cancer patients.26 
Though high-energy radiation can fatally damage tumor cells, it can also harm 
normal tissues. Hence, it is very important to strike the right balance between 
eradicating tumor and saving normal tissues by controlling the target and the 
dose of radiation administered to the patient. Many improvements have been 
made in radiotherapy to target tumors better and cause less damage to normal 
tissues. For example, megavolt (6–25 MV) X-rays are now used to avoid skin 
damage; tomotherapy and intensity-modulated radiation therapy (IMRT) are 
applied to better concentrate the radiation within the tumor volume; optimal 
dose fractionation schedules are also developed to allow better cumulative 
damages to the tumor and adequate repairing of normal tissues.27, 28 Despite 
such advances, it is still challenging to use radiotherapy alone to eradicate tumor 
cells. A magic bullet to current challenges in radiotherapy is radiosensitizer, 
which can locally increase the efficacy of radiotherapy by enhancing the 
radiation damages to the cell. 
Metal-based radiosensitizers can strongly absorb, scatter, and reemit 
radiation energy, resulting in a local radiation dose increase when they are 
accumulated in tumors.29, 30 Intense research on metal nanomaterials in the past 
two decades has provided many novel materials for biomedical applications.31-
33 Among these emerging radiosensitizers, gold nanoparticles (Au NPs) are 
particularly attractive because of their strong interaction with the radiation (Au 
has a high atomic number of 79), excellent chemical stability and inertness, and 
good biocompatibility (low toxicity)34-37. The enhancement of radiation dose 
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received by the tumor tissue loaded with Au relative to the dose received by 
normal tissues without Au can be 200% or higher38, 39. Such enhancement comes 
from the direct interaction between Au and radiation. When the incident 
radiation (gamma rays, X-rays) impinges on a Au NP, the NP becomes a new 
source of radiation and emits high energy through scattered photons (X-rays), 
photoelectrons, Compton electrons, Auger electrons, electron–positron pairs, 
and fluorescence photons, thereby causing radiochemical (free radicals and 
ionization) damages to the surrounding tumor tissue.38, 40, 41 However, most of 
the Au NPs that have been demonstrated so far have large particle sizes 
(typically above 50 nm) and could be trapped by the reticuloendothelial system 
(RES) absorption, which could result in low tumor uptake and unavoidable 
accumulation in liver and spleen.42-48 Decreasing the particle size could benefit 
the escape of particles from the RES absorption. For example, one recent study 
showed that Au NPs with sizes <20 nm could efficiently escape the RES 
absorption and showed good tumor uptake.49 Thus, ultrasmall Au NCs with 
metallic Au core sizes smaller than 2 nm are promising biocompatible and renal 
clearable radiosensitizers. 
Besides the core sizes of Au NPs, the protecting ligands on the NP surface 
can also make or break the in vivo biodistribution. For example, naked 1.9 and 
4.8 nm Au NPs while small, have low colloidal stability due to the protein 
corona acquired in blood. These NPs eventually formed large 20-100 nm 
aggregates which could not be rapidly metabolized and certainly unable to 
escape RES.34, 50 Au NPs with different surface ligands can induce different 
NPs-protein corona in blood that could determine the RES absorption and 
cellular uptake efficiency.51-54 Therefore, thiol-protected Au NCs (thiolated Au 
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NCs) are chosen as the model noble metal NCs for applying as the 
radiosensitizer. Thiols can provide strong protection for the Au NCs by forming 
covalent-like strong Au–S bond with the Au core, which allows the thiolated 
Au NCs to have ultrahigh chemical stability.1 Small water-soluble biothiols, 
such as L-glutathione (GSH) and L-cysteine (Cys), are expected to be highly 
biocompatible and can prevent the formation of large protein corona around the 
Au NCs, so the hydrodynamic diameter of biothiol-protected Au NCs is  
expected to be smaller than the threshold of kidney filtration (~5.5 nm).55 Thus, 
biothiol-protected Au NCs are likely to be biocompatible and renal clearable. 
An added advantage of the thiolated Au NCs is their photoluminescence 
properties. Thiolated Au NCs are widely reported to show orange to near-IR 
emission, which may provide a platform for real-time in vivo imaging of the 
biodistribution of the NCs.17, 56 Thus, thiolated Au NCs are promising 
theranostic radiosensitizers and are the target of our bio-integrated synthesis. 
 
 
1.2 Research Objectives 
To achieve the ideal bio-integrated synthesis, it is essential to first understand 
the requirements for applying noble metal NCs in the specific biomedical 
application. Such requirements serve as the design criteria of bio-integrated 
synthesis. However, to realize the desired properties or to fulfill the design 
criteria of the bio-integrated synthesis, fundamental understanding about the 
properties of noble metal nanoclusters and effective methods or technologies to 
precisely controlling the properties of the NCs are absolutely necessary. Despite 
the fact that thiolated Au NCs have been the most studied noble metal NCs in 
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the past two decades, there are still challenges in controlling the properties of 
the NCs, including the photoluminescence (PL) and the size of the NCs, which 
are critical for applying the NCs as theranostic radiosensitizers. For examples, 
few efficient synthesis methods exist for synthesizing highly luminescent 
thiolated Au NCs, and the quantum yields (QYs) of thiolated Au NCs 
synthesized from the most commonly used “modified” Brust method rarely 
exceeds 0.1%. The current synthesis of highly monodisperse water-soluble 
thiolated Au NCs are limited to relatively small NCs (less than 29 Au atoms), 
and no aqueous synthesis can produce thiolated Au NCs with a few hundred 
atoms.1, 57 
The lack of synthesis methods for highly luminescent thiolated Au NCs and 
for monodisperse NCs with relatively larger sizes could be attributed to the lack 
of fundamental understanding about the photoluminescence (PL) and the 
formation mechanisms of the NCs. With these considerations, this thesis project 
aims to focus on (1) understanding the fundamental issues of the PL of thiolated 
Au NCs such as the origin of PL, the size effects on the emission energy, and 
the critical factor that affects the QYs of the NCs and developing new synthetic 
strategies to synthesize highly luminescent thiolated Au NCs, (2) understanding 
the formation mechanism of thiolated Au NCs and developing syntheses for 
relatively large (>Au29) monodisperse water-soluble NCs, and (3) 
understanding the in vivo behavior (e.g., pharmacokinetics and biodistribution) 






1.3 Thesis Outline 
This doctoral thesis consists of eight chapters. Chapter 1 describes the general 
research background, the motivation, objectives, and outline of this thesis 
project. Chapter 2 reviews the literature for general biological considerations in 
designing NCs for in vivo biomedical applications, current synthetic strategies 
for synthesizing biocompatible water-soluble Au/Ag NCs, and a few exemplary 
biomedical applications.  
Chapter 3 and 4 focus on our understanding of the PL properties of the 
thiolated Au NCs. Chapter 3 discusses our discovery the of the aggregation-
induced emission (AIE) of Au(I)–thiolate complexes and the development of 
the facile synthesis of highly luminescent biothiol-protected Au NCs with PL 
originated from the AIE of the Au(I)–thiolate motifs on the NC surface. Chapter 
4 discusses the source of emission, the origin of the excitation, and the QYs of 
near-IR and visible luminescence of thiolated Au NCs synthesized from the 
most common synthesis method “modified” Brust method. 
Chapter 5 and 6 focus on our studying on the formation mechanism of the 
thiolated Au NCs and the development of a facile aqueous synthesis of highly 
monodisperse ~2 nm thiolated Au NPs. Chapter 5 discusses the growth 
mechanism from reduction of Au(I)–thiolate complex precursors to atomically 
precise thiolated Au25 NCs. Inspired by the growth mechanism, we discuss the 
development of a facile aqueous synthesis of highly monodisperse ~2 nm 
thiolate NPs in Chapter 6. 
Chapter 7 represents our in vivo study of a biothiol-protected Au NCs 
synthesized from bio-integrated synthesis as a biocompatible, renal clearable, 
and effective radiosensitizer.  
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CHAPTER 2    
Engineering Ultrasmall Water-Soluble Noble Metal 
Nanoclusters for Biomedical Applications 
2.1 Introduction 
Many synthetic strategies have been recently developed for the preparation of 
noble metal NCs, particularly Au/Ag NCs, with predesigned attributes, such as 
size monodispersity and strong photoluminescence.1-6  For biomedical 
applications, the design of functional Au/Ag NCs and their subsequent 
performance in biological systems is largely influenced by the interactions 
between the Au/Ag NCs and the biological systems. Many attributes of the 
Au/Ag NCs including the water solubility, chemical stability, size, and surface 
can affect these interactions. The NC attributes can be independently designed 
and engineered to cater for a particular biomedical application and achieve a 
required performance. As illustrated in Scheme 2.1, a Au/Ag NC typically has 
a core-shell structure that consists of a metal core and an organic ligand shell. 
Both the metal core and the organic shell of the NCs could be independently 
tailored to realize a predesigned property. For example, the size of the metal 
core, which is known to be crucial for the optical and catalytic properties of the 
NCs, can be tailored by adjusting the type of ligand, ligand-to-metal ratio, the 
strength of the reducing agent, and other experimental conditions, such as 
reaction temperature, solvent conditions, and reaction time.1, 2, 4, 5 Similarly, the 
ligand shell can be tailored by using different types of organic ligands (e.g., 
biomolecules, polymers, and dendrimers), or ligands with different sizes, 
functional groups, and surface charges. The ligand shell is the outer layer of the 
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Au/Ag NCs and directly interacts with the biological systems. As a result, the 
ligand shell could control the biocompatibility of the NCs. An efficient strategy 
to mitigate this biocompatibility issue is to use naturally occurring 
biomolecules, such as proteins, peptides, and DNAs, to fabricate Au/Ag NCs, 
leading to the formation of NCs with a biogenic ligand shell that may have 
excellent biocompatibility. This concept has been successfully demonstrated in 




Scheme 2.1 Schematic illustration of the core-shell structure of protein- and 
peptide-protected Au/Ag NCs. 
 
In this chapter, we first discuss some critical considerations, from the 
biological perspective, in the design of functional Au/Ag NCs for biomedical 
applications, especially those for in vivo settings. According to these biomedical 
considerations, we then survey some efficient synthetic strategies for functional 
Au/Ag NCs, with a particular emphasis on those strategies using biomolecules 
as active organic ligands for the synthesis of Au/Ag NCs. In the last section, we 
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2.2 Biomedical considerations of Au/Ag NCs 
In any design of functional nanomaterials for practical applications, the 
identification and understanding of the design criteria in a particular application 
are pivotal to engineer high quality nanomaterials that can achieve the required 
performance. For the biomedical applications of Au/Ag NCs, it is important to 
ensure that the undesired biological impacts of the NCs can be minimized. 
Biocompatibility and renal clearance are two key issues to consider in the design 
of Au/Ag NCs for biomedical applications and will be discussed in detail in this 
section. 
 
2.2.1 Biocompatibility issue of Au/Ag NCs 
The biocompatibility is an important parameter in assessing both the short- and 
long-term host response of the materials that are applied in biological systems.10 
When the NCs are injected into an organism or enter a cell, the NCs could harm 
the host through the interactions with the host environment, such as inducing 
oxidative stress by generating free radicals, binding to the host proteins and 
other biomolecules, triggering an immunological response (e.g., inflammation), 
and breaking down and releasing toxic ions from the inorganic core.11-14 There 
are many ways to improve the biocompatibility of metal nanomaterials, such as 
coating toxic metal core with a nontoxic shell (e.g., ZnS) and functionalizing or 
replacing hydrophobic ligands with a more hydrophilic and biocompatible 
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molecule.15-17 However, the best approach to ensure the biocompatibility of the 
final product would be to eliminate the usage of toxic or non-biocompatible 
building blocks of the nanomaterials by design.18 
As illustrated in Scheme 2.1, the two major building blocks of the NCs are 
the metal core and the ligand shell. The choices of the core and the shell 
materials are critical for the biocompatibility of the resultant NCs. The metal 
used for the core should not include toxic metals such as Cd, Pb, and Hg. In 
addition, the metal should be chemically inert so that it can maintain the 
structural integrity of the NCs and prevent undesired decomposition in the 
biological systems. Thus, noble metals like Au and Ag are the most attractive 
candidates in preparing functional NCs for biomedical applications because of 
their relatively low toxicity and high inertness. Au and Ag are known to have 
strong interaction with soft ligands such as phosphine, thiolate, and selenolate; 
therefore, the resultant NCs consisting of Au/Ag and the soft ligands are 
expected to have high stability. For example, thiolate- and selenolate-protected 
Au25L18 NCs (L denotes the ligand) have been reported to have extraordinary 
stability in solution.19, 20As compared with the metal cores, the ligand shell 
serves as the interface between the NCs and the biological environment. Thus, 
the ligand shell dictates the interactions between the NCs and the biological 
system and should receive more attention in the design. The biocompatibility of 
the coating ligands of relatively large NPs (>2 nm) has been an extensive 
research subject in the last two decades, which allows us to have a better 
understanding of the requirements to improve the biocompatibility of the NC 
shell in the design of the Au/Ag NCs.11, 12, 17 Some key parameters that are 
determined by the surface shell include the water solubility (or colloidal stability 
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in aqueous phase), surface charges, and functional groups. An ideal choice that 
can ensure good biocompatibility of the surface shell is to use the naturally 
occurring biomolecules, including proteins and peptides, as the active organic 
ligands in synthesizing Au/Ag NCs. The biogenic shell of the NCs formed by 
proteins and peptides can ensure good colloidal stability and solubility of the 
NCs in biological systems. It can also mimic the surface of the naturally 
occurring proteins, thereby avoiding undesired (or nonspecific) binding with 
proteins like serum albumin. 
 
2.2.2 Renal clearance issue of Au/Ag NCs 
Renal clearance of nanomaterials is a critical factor in determining the long-
term toxicity of the nanomaterials; poor renal clearance could potentially 
amplify the toxicity of the nanomaterials. In addition, for diagnostic agents, 
incomplete clearance could result in interference with future diagnostic tests. 
The key parameters of the nanomaterials that determine their renal clearance 
include the hydrodynamic diameter (HD) and surface charge. Only 
nanomaterials (e.g., molecules and ions) with a HD below the kidney filtration 
threshold (about 5.5 nm) can be rapidly and efficiently cleared by the kidney.18 
The HD of the NCs is dictated by both the metal core and the ligand shell. The 
size of the metal core mainly depends on the number of metal atoms. In general, 
Au/Ag NCs contain less than 150 atoms and have core sizes of 2 nm or below. 
However, the thickness of the ligand shell could vary much more significantly 
than the metal core with differences in both the number and the types of the 




Another critical parameter that could influence the renal clearance of the 
NCs is their surface charge. Au/Ag NCs used in biomedical applications are 
typically water-soluble. They can carry pure anionic, pure cationic or mixed 
(zwitterionic) charge under the physiological conditions. The charges on the 
NCs depend on the number and types of the charged functional groups of the 
ligand shell. The most common functional Au/Ag NCs have pure anionic or 
zwitterionic. For example, Au/Ag NCs protected by mercaptocarboxylic acids 
[e.g., 3-mercaptopropionic acid (3-MPA) or p-mercaptobenzoic acid (p-MBA)] 
carry pure negative charges imparted from the carboxylic groups on the NC 
surface.22, 23 Similarly, Au/Ag NCs protected by ligands containing both 
carboxylic and amine groups, which are common functional groups in peptides 
and proteins, are zwitterionic.7, 8 Au/Ag NCs with pure cationic charge have 
also been prepared using a ligand made of lipoic acid appended with an amine-
functionalized poly(ethylene glycol) chain.24, 25 
The surface charge of the Au/Ag NCs could have significant effects on their 
renal clearance by affecting the solubility, absorption of serum proteins, and the 
HDs of the NCs.18, 26 The HDs of nanomaterials that carry purely anionic or 
cationic charge will increase after incubation in serum. In contrast, 
nanomaterials with a zwitterionic surface have much better solubility and much 
smaller changes in HD in serum. Therefore, biomolecules that are small and 
zwitterionic, such as cysteine, peptides, and proteins, are ideal ligand candidates 





2.3 Engineering approaches for Au/Ag NCs for biomedical 
applications 
As discussed above, the ligand shell of Au/Ag NCs determines the interaction 
between the NCs and the biological systems, and an ideal choice of the NC 
surface is a biogenic shell consisting of biomolecular ligands, such as proteins 
and peptides. In this section we discuss the synthesis strategies for high quality 
Au/Ag NCs according to the types of biomolecules used as the protecting agent 
and the approaches to functionalizing the surface of the NCs. 
 
2.3.1 Protein-protected Au/Ag NCs 
Protein-protected Au/Ag NCs are similar to the naturally occurring 
metalloproteins or proteins with metal ion cofactors, such as hemoglobin and 
superoxide dismutase. They can be considered as modified natural proteins and 
have great potential in biomedical applications because of their inherent good 
biocompatibility. Both the metal core and the protein shell of the NCs contribute 
to the physicochemical characteristics of the NCs, such as photoluminescence, 
antimicrobial activity, hydrodynamic diameter, and surface charge. Hence, a 
synthetic approach that is robust and efficient, and readily allows the tuning of 
the core-shell structure of the protein-protected Au/Ag NCs is pivotal to 
engineering such Au/Ag NCs for biomedical applications.  
Xie et al. first developed a facile one-pot synthesis for highly luminescent 
Au NCs protected by a commercially available protein, bovine serum albumin 
(BSA).7 Their synthesis is illustrated in Scheme 2.2. In a typical synthesis, an 
aqueous solution of HAuCl4 was mixed with a BSA solution under vigorous 
stirring at the physiological temperature of 37 °C. After a short incubation 
period, the pH of the reaction mixture was adjusted to ~12, which could activate 
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the reducing power of BSA molecules and therefore progressively reduce the 
entrapped Au ions to form Au NCs in situ. The resultant BSA-protected Au NC 
consists of 25 Au atoms that were encapsulated within the BSA molecule and 
exhibited strong red luminescence (λem, max = 640 nm, quantum yield or QY = ~ 
6%). Such strong luminescence allowed the use of the BSA-protected Au NCs 
in sensing and bioimaging applications.27, 28 In addition, the strong protection 
from the Au–S bonding (the thiol groups are from cysteine residues of BSA) in 
combination with a good steric protection from the bulky BSA molecule, 
imparted the Au NCs good stability in a variety of aqueous solution conditions, 
such as different pHs, high salt concentrations, and various buffers. The high 




Scheme 2.2 Schematic illustration of the formation process of BSA-
protected Au NCs. Reprinted with permission from Ref 7. Copyright 2009 
American Chemical Society. 
 
The above described synthesis approach is generally termed as “protein-
directed” synthesis to highlight the crucial roles of the protein in the reactions, 
which include serving as the template for the in situ reduction of Au/Ag ions, 
as the protecting agent for the as-synthesized Au/Ag NCs, and as the reducing 
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agent to reduce Au/Ag ions.31 In a typical protein-directed synthesis, the protein 
molecules first sequestrate, interact with and provide scaffolds or templates to 
the Au or Ag ions, and then the entrapped Au/Ag ions are reduced by a strong 
reducing agent (e.g., NaBH4) or the reducing functional groups in the protein 
(e.g., side groups of tyrosine and tryptophan residues).32, 33 The simple reaction 
setup and one-pot manner, and the use of mild reaction conditions and 
biocompatible reactants and products, have made the protein-directed synthesis 
an ideal and green platform for the preparation of protein-protected Au/Ag NCs 
in quantities large enough for practical applications. 
The protein-directed syntheses have been demonstrated to be fairly robust 
and versatile, and are therefore attractive for engineering protein-protected 
Au/Ag NCs with desired and predesigned characteristics. The core-shell 
structure of the NCs could be readily tuned by choosing the suitable reactants, 
that is, the protein and metal ion precursors, and by optimizing critical reaction 
conditions including the solution pH, solvent conditions, and the reaction 
temperature. Besides serum proteins like BSA, many other proteins, such as 
lysozyme,34, 35 lactoferrin,36 pepsin,37 trypsin,38 insulin39 and horseradish 
peroxidase,40 have also been used to synthesize protein-protected Au/Ag NCs 
41, 42 using synthesis conditions that are similar to that of the BSA-Au NCs. 
Different proteins can impart very different hydrodynamic diameters, surface 
charges, and functional groups to the resultant protein-protected NCs because 
of the difference in the primary structure of the protein (the number and 
sequence of the amino acid residues). For example, BSA-Au NCs are 
negatively-charged while lactoferrin-Au NCs are positively-charged at the 
physiological pH of 7.4.7, 36 The choice of metal elements in the NC core also 
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determines the properties of the protein-protected NCs. For example, protein-
protected Au NCs are generally considered as stable and non-toxic, however, 
the Ag in Au/Ag bimetallic NCs could impart antimicrobial activity and also 
help tune the optical properties (e.g., emission wavelengths) of the NCs.42, 43 
The pH of the reaction mixture is critical in controlling not only the reducing 
power of the protein but also the protein conformation and the stabilizing 
capability of the protein, by affecting the bonding or chelation between the 
functional groups of the protein and the metal. Thus, pH could determine the 
number and arrangement of the metal atoms in the protein, thereby controlling 
the size and properties of the resultant protein-protected NCs. For example, 
Guével et al. have synthesized two different types of BSA-protected Au NCs by 
only adjusting the pH of the reaction mixture.44 The blue-emitting (λem, max = 
450) Au NCs synthesized at pH 8 consisted of eight Au atoms that were loosely 
bound to the protecting BSA molecule, whereas the red-emitting (λem, max = 690 
nm) Au NCs formed at pH 11 consisted of 25 Au atoms that were strongly 
bound to the BSA through the Au–S bond. In addition, Au(I) was only present 
in the red-emitting Au NCs. Last, other reaction conditions such as the metal-
to-protein ratio and external energy input (e.g., direct heating, microwave, and 
ultrasonic irradiation) could also be optimized to tune the size of the Au NCs, 
thereby improving the yield and shortening the reaction time for the desired NC 
product.42, 45-47  
Another attractive feature of the protein-directed synthesis of Au/Ag NCs is 
its capability of retaining the bioactivity of the protein during and after the 
synthesis. This could be attributed to the relatively mild reaction conditions and 
the ultrasmall size of the metal core of the NCs, which could largely limit the 
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changes in the protein conformation and functional groups and preserve the 
active sites of the protein. The bioactivity of the protein could be used to control 
the synthesis of the NCs. For example, Kawasaki et al. utilized the bioactivity 
of pepsin during the synthesis of green-emitting Au NCs that consisted of 13 
Au atoms by using an acidic pH (~1).37 As illustrated in Scheme 2.3, at low pH 
of 0.6–2, pepsin functioned best as a digestive protease and could catalyze its 
autolysis, which was confirmed by the mass spectrometric analysis of the 
autolysis products of pepsin. When an alkaline pH of 10–13 was used, red-
emitting Au25 NCs protected by denatured pepsin were formed and the autolysis 
activity of pepsin was annulled due to large conformational changes of pepsin 
as suggested by circular dichroism results. As expected, the polyacrylamide gel 
electrophoresis (PAGE) data showed that the green-emitting Au13 NCs (<6.5 
kDa) were much smaller than the red-emitting Au25 NCs (29.0–44.3 kDa), 
suggesting that the Au13 NCs were likely to be protected by peptides formed 
from the autolysis of pepsin. The bioactivity of the protein shell of the NCs 
could also be preserved so that the resultant NCs can fulfill the original 
biological role of the protein. For example, Liu et al. demonstrated an insulin-
directed synthesis of red-emitting Au NCs that retained the insulin bioactivity.39 
The in vivo study showed that the blood glucose level can be successfully 
regulated by these insulin-protected Au NCs. In addition, the insulin degrading 
enzyme (IDE) that specifically degrades and inactivates insulin via proteolysis 
was able to significantly quench the luminescence of the Au NCs by degrading 





Scheme 2.3 Schematic illustration of pepsin-directed synthesis of Au NCs 
with different emission colors. The bioactivity of pepsin, a digestive protease, 
was preserved at pH 0.6–2 and facilitated the synthesis of green-emitting Au13 
NCs. Adapted with permission from Ref 37. Copyright 2011 Wiley-VCH. 
 
The facile and robust protein-directed synthesis of Au/Ag NCs has been 
successful in making protein-protected NCs with desired properties such as high 
biocompatibility, strong luminescence, and preserved bioactivity. It also 
prompted strong interests in understanding the structure and the growth 
mechanism of the protein-protected NCs.45, 48 However, due to the complexity 
of the protein template and the interaction between the metal and the protein, it 
is difficult to obtain protein-protected NCs with uniform size and structure for 
the accurate determination of their structures by methods such as X-ray 
crystallography. Thus, the actual structure of the NCs has yet to be elucidated.48 
Alternative indirect measurement methods such as mass spectrometry and X-
ray absorption spectroscopy have been used to help shed light on the structure 




2.3.2 Peptide-protected Au/Ag NCs 
Peptides are short chains of amino acids. Naturally occurring peptides have 
significant biological roles such as hormones, antibiotics, and anti-oxidants. 
Similar to proteins, peptides can be used to stabilize Au/Ag NCs and impart 
good biocompatibility and bioactivity to the resultant NCs. Most importantly, 
thanks to the advancement in the chemical synthesis of peptides, short custom-
designed peptides with specific amino acid sequences can be readily obtained, 
which allows the rational design of the peptide ligands with specific properties, 
such as size, charge, reducing power, and targeting capability, for the synthesis 
of biocompatible and functional peptide-protected Au/Ag NCs for biomedical 
applications. 
Thiol group is essential for the synthesis of stable peptide-protected Au/Ag 
NCs because of the strong bond formation between sulfur and Au/Ag which can 
stabilize the NCs. Thus, thiol-containing amino acids, such as Cys and 
homocysteine (Hcy), and thiol-containing peptides, such as the ubiquitous Cys-
containing tripeptide glutathione (GSH or H-SG), are commonly used as the 
ligand for the synthesis of peptide-protected Au/Ag NCs.8, 22 Besides stabilizing 
the resultant NCs, thiols can also help reduce and coordinate with metal ions to 
form complexes that are common intermediates in the synthesis of thiolate-
protected Au/Ag NCs. Moreover, thiols are able to etch larger NCs or NPs to 
reduce their sizes and improve their size monodispersity. Chemical etching by 
free thiols has been known to be a feasible method for core‐size reduction of the 
thiolated Au NCs. The exact mechanism is still not clear, but it has been 
considered as analogous to the etching process occurred in exposure of bulk 
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gold to thiol solutions, where Au atoms are removed from the outermost surface 
layer.19, 50 
The syntheses of Au/Ag NCs protected by thiol-containing peptides are 
similar to the syntheses of NCs protected by other types of thiolate ligands. 
Since the pioneering work of Brust et al. in the early 1990s, the most common 
metal source for the syntheses of thiolate-protected Au/Ag NPs or NCs are 
metal ions [e.g., Au(III) and Ag(I)].51 For example, in the original Brust-
Schiffrin synthesis, the Au(III) ion source HAuCl4 was first transferred from 
aqueous phase to toluene by a cationic phase-transfer agent and then reduced by 
NaBH4 in the presence of thiolate ligands. Many groups including Murray, 
Whetten, Tsukuda, Jin and others carried out extensive work to modify the Brust 
synthesis to reduce the size of the resultant Au NCs to sub-2 nm regime and 
improve their monodispersity.5, 8, 52-65 The modified Brust method has been 
routinely used to synthesize thiolate-protected Au NCs and used as a starting 
point for designing synthetic approaches to NCs with desired properties. The 
well-developed modified Brust synthesis comprises two major reaction steps: 
(I) Reduction of Au(III) to Au(I)–SR complexes 
Au(III) + 3 HSR → Au(I)–SR complexes + RS–SR                                 (1) 
(II) Reductive decomposition of Au(I)–SR complexes to Aun(SR)m (reaction is 
not balanced) 
Au(I)–SR complexes + reductant (e.g., NaBH4) → Aun(SR)m                  (2) 
The completeness of the reaction shown in Eqn (1) is determined by the thiol-
to-Au(III) ratio in the reactants. The thiol-to-Au(III) ratio in the reactants also 
determines how well the in situ generated Au NCs are protected from the 
Chapter 2 
26 
aggregation and growth, and how strong the thiol etching effect is. Taken 
together, the thiol-to-metal ratio in the reactants is a critical factor that can 
determine the conversion chemistry, therefore in this section we discuss the 
synthetic strategies of Au/Ag NCs according to whether the thiol-to-metal ratio 
is sufficiently high to yield only homoleptic thiolate-coordinated complex 
intermediates. 
As suggested by Eqn (1), the thiol-to-Au ratio needs to be at least 3:1 to 
ensure the Au(I) is fully coordinated with thiolate ligands. However, it is worth 
noting that besides the thiol group, the disulfide group (from RS–SR) and other 
functional groups of the thiol-containing peptides can also reduce Au(III) to 
Au(I) in aqueous solution.33, 66-68 Thus, the minimum thiol-to-Au ratio required 
to fully coordinate Au(I) with thiol-containing peptide ligands can be less than 
3:1 and can differ for different peptides involved in the synthesis. For example, 
if GSH is used as the ligand, a thiol-to-Au ratio of 2:1 is sufficient to reduce all 
Au(III) and fully coordinate the resultant Au(I) with thiolate groups at acidic or 
neutral pH.66 The theoretical lower boundary for the sufficient thiol-to-Au ratios 
would be 1:1, which corresponds to the case that thiols are not consumed in the 
reduction of Au(III) and only participate in the coordination with Au(I) to form 
polymeric or cyclic homoleptic Au(I)–thiolate complexes. 
 
2.3.2.1 Synthesis of Au/Ag NCs using high thiol-to-metal ratios 
When high or sufficient thiol-to-metal ratio is used [e.g., 3:1 for Au(III) and 2:1 
for Ag(I)], metal ions can be coordinated almost completely by thiolate ligands 
to form homoleptic metal–thiolate complexes. Because of the strong metal–S 
bond, the metal–thiolate complexes are more stable than non-thiolate 
coordinated metal complexes in aqueous phase. For example, as compared with 
Chapter 2 
27 
AuCl, which could quickly decompose to form Au(0) and Au(III) in water under 
heating, homoleptic Au(I)–SR complexes [e.g., polymeric Au(I)–SG 
complexes] is stable against heating in water (e.g., at 70 °C for 24 h).66 Thus, a 
relatively strong reducing environment is usually required to reductively 
decompose the homoleptic metal–thiolate complexes to form metal atoms (with 
an oxidative state of 0) and metal-thiolate complex motifs that lead to the 
formation of NCs. 
Borane-based strong reducing agents, such as NaBH4, are routinely used to 
reductively decompose homoleptic metal-thiolate complexes. For example, 
mixtures of different-sized GSH-protected Au NCs could be synthesized using 
a GSH-to-Au ratio of 3:1 and NaBH4 (NaBH4-to-Au ratio = 10:1) as the 
reducing agent.8 Negishi et al. carried out a similar synthesis (GSH-to-Au ratio 
= 4:1, and NaBH4-to-Au ratio = 10:1) and successfully identified nine Au NC 
species with discrete sizes [from Au10(SG)10 to Au39(SG)24] by using PAGE.
69 
Similarly, Kumar et al. synthesized a mixture of GSH-protected Ag NCs with 
at least 16 discrete sizes by using a GSH-to-Ag ratio of 4:1 and NaBH4 (NaBH4-
to-Ag ratio = 10:1) as the reducing agent.70 As shown in these studies, the as-
synthesized peptide-protected Au/Ag NCs from general modified Brust 
syntheses often have a wide size distribution. In addition, the 
photoluminescence from these NCs was also relatively weak (QY ~ 0.1%).69 
Tremendous efforts have been devoted to developing efficient synthetic 
strategies to improve the monodispersity or enhance the photoluminescence of 
the peptide-protected Au/Ag NCs, such as applying thiol etching or “size-
focusing”, manipulating the metal-thiolate complex intermediates, and slowing 
down the reduction kinetics.4 For example, Shichibu et al. studied the reactivity 
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of different-sized GSH-protected Au NCs [from Au10(SG)10 to Au39(SG)24] 
towards free GSH under aerobic conditions and found that Au25(SG)18 was 
much more resistant against thiol etching as compared with other NCs.19 On the 
basis of this size-dependent stability, they demonstrated that Au25(SG)18 could 
be selectively synthesized by reacting a mixture of different-sized GSH-
protected Au NCs (obtained from a modified Brust synthesis) at an elevated 
temperature (328 K) for 3 h. However, the thiol etching process requires delicate 
control to prevent excessive decomposition. As demonstrated by Yuan et al., 
the polydisperse non-fluorescent GSH-protected Ag NCs synthesized using a 
GSH-to-Ag ratio of 3:1 and excess NaBH4 (NaBH4-to-Ag ratio of ~ 2.2:1) can 
be rapidly degraded to Ag(I)-SG complexes (in 2.5 h) via the thiol etching 
process by the excess free GSH in the aqueous reaction mixture.71 Thus, they 
developed an electrostatically-induced reversible phase transfer protocol to 
control the etching environment for the synthesis of monodisperse and 
luminescent GSH-protected metal NCs. As illustrated in Scheme 2.4, the 
polydisperse GSH-protected Ag NCs were first transferred into the toluene 
phase by a cationic surfactant (e.g., CTAB), leaving most of the excess free 
GSH in the aqueous phase. The thiol etching occurring in the toluene phase was 
much slower and milder relative to that in the original aqueous reaction mixture 
of the polydisperse GSH-protected Ag NCs, and was able to convert the Ag 
NCs into monodisperse (as suggested by their well-defined UV–vis absorption 
spectrum and elemental analysis) and luminescent Ag NCs. After the 
completion of the etching process, the resultant Ag NCs can be easily shuttled 
back to aqueous using an anionic surfactant. The mild etching environment 
introduced by the phase transfer process is very robust and versatile in making 
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luminescent NCs of other metal elements (e.g., Au, Pt, and Cu) and other 
peptide ligands (custom-designed cysteine-containing tripeptides). 
 
 
Scheme 2.4 Schematic illustration of the phase transfer cycle that 
transformed polydisperse non-luminescent GSH-protected metal (Ag, Au, Pt, 
and Cu) NCs to monodisperse luminescent NCs. Reprinted with permission 
from Ref 71. Copyright 2011 American Chemical Society. 
 
The properties of metal-thiolate complex intermediates [Eqn (1) and (2)], 
such as their size, structure, and concentration, can also be manipulated to tune 
the modified Brust syntheses of peptide-protected NCs for monodispersity and 
strong luminescence. For example, Yuan et al. developed a cyclic reduction-
decomposition process (Scheme 2.5) to tune the size of the Ag(I)-thiolate 
complex intermediates for the synthesis of monodisperse and luminescent 
peptide-protected Ag NCs.72 Relatively polydisperse Ag(I)-SG complex 
intermediates were first formed using a GSH-to-Ag ratio of 3:1. These 
complexes were then reduced with NaBH4 (NaBH4-to-Ag ratio of ~2.2:1), 
followed by etching by the excess free GSH in the aqueous reaction mixture 
under aerobic conditions for ~3 h, which resulted in the formation of smaller 
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and more monodisperse Ag(I)-thiolate complex intermediates. Subsequently, 
these intermediates were reduced by NaBH4 to form red- and green-emitting Ag 




Scheme 2.5 Schematic illustration of the cyclic reduction-decomposition 
process for controlling the size of the Ag(I)-SG complex intermediates for the 
synthesis of monodisperse and luminescent GSH-protected Ag NCs. Reprinted 
by permission from Macmillan Publishers Ltd: NPG Asia Materials (Ref 72), 
copyright 2013. 
 
The synthesis of monodisperse peptide-protected metal NCs could also be 
achieved by slowing down the reduction kinetics. Yao et al. developed a one-
pot two-phase synthesis method that employed two approaches to reduce the 
reduction kinetics for the synthesis of monodisperse Au15(SG)13 and Au18(SG)14, 
that is, limiting the concentration of the soluble Au(I)-SG complex intermediate 
and adding an organic phase that contains a relatively less reactive reducing 
agent (Scheme 2.6).73 The concentrations of the soluble Au(I)-SG complexes 
were regulated by controlling the pH-sensitive aggregation-dissociation 
equilibrium of the Au(I)-SG complexes. The pH can determine the net charges 
on GSH ligands, thereby affecting the solubility of the Au(I)-SG complexes. 
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Borane tert-butylamine (TBAB), which is a relatively weaker reducing agent 
than NaBH4, was dissolved in toluene before adding to the aqueous solution of 
the Au(I)-SG complexes. The choice of the relatively weak TBAB, in 
combination with the two-phase design, which limits the reduction rate by 
introducing a diffusion process of TBAB from the organic to the aqueous phase, 
effectively created a slower and more controllable reducing environment for the 
synthesis of monodisperse peptide-protected Au NCs. 
 
 
Scheme 2.6 Schematic illustration of the two-phase synthesis of 
monodisperse Au15(SG)13 and Au18(SG)14. Reprinted with permission from Ref 
73. Copyright 2013 Wiley-VCH. 
 
2.3.2.2 Synthesis of Au/Ag NCs using insufficient thiol-to-metal ratios 
Low and insufficient thiol-to-metal ratios [e.g., 1.5:1 for Au(III) and 0.5:1 for 
Ag(I)] can result in the formation of non-thiolate-coordinated Au/Ag 
complexes. Non-thiolate ligands in the reaction mixture, such as chloride and 
carboxylic ions, have weaker affinity to the Au/Ag ions as compared with 
thiolate ligands, thereby causing the non-thiolate-coordinated Au/Ag complex 
intermediates less stable and more reactive towards reducing agents. Thus, mild 
reducing agents such as carbon monoxide (CO) and the reducing functional 
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groups on the peptide ligands are ideal the syntheses that start with insufficient 
thiol-to-metal ratios to produce monodisperse or luminescent peptide-protected 
Au/Ag NCs. 
The gaseous reductant CO is widely used as a mild reducing agent and a 
stabilizer for noble metal NP syntheses.74-77 However, its usage for NC synthesis 
is a more recent discovery. Yu et al. first developed an efficient synthetic 
approach for large-scale production of monodisperse peptide-protected 
Au25(SR)18.
22 In a typical synthesis, HAuCl4 first reacted with thiol-containing 
amino acid (e.g., Cys) or peptide (e.g., GSH) with a thiol-to-Au ratio of 1.5:1, 
followed by the adjustment of pH to 11. The reaction vessel was then saturated 
with 1 bar CO for 2 min and sealed airtight, and the reaction was allowed to 
proceed for 24 h at room temperature. As shown in Scheme 2.7a–d, the well-
defined UV–vis and clean ESI-MS spectra suggested the atomic precision of the 
as-synthesized Au25(Cys)18. In addition to the capability of large-scale 
production of atomically precise Au25(SR)18 NCs, the slow and controllable 
reaction kinetics also allowed the observation of the remarkable color and 
absorption spectral evolution and measurement of the growth of the NCs by 
matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass 
spectrometry. As illustrated in Scheme 2.7e, large-scale syntheses of other sized 
Au NCs, such as Au10(SG)10, Au15(SG)13, and Au18(SG)14, could be readily 
achieved by fine-tuning the reaction pH of the CO-mediated syntheses.78 The 
reaction pH could significantly affect the reducing capability of CO, and thereby 
affecting the reaction kinetics. It was proposed that the formation kinetics of the 
Au NCs increases as the pH increases. Thus, a lower pH can facilitate the kinetic 





Scheme 2.7 (a) UV–vis spectrum and (b–d) ESI spectra of the as-synthesized 
Au25(Cys)18 NCs. The blue line in (d) is the simulated isotope pattern of peak 
#4 in (c). (e) Schematic illustration of the pH-controlled synthesis of different-
sized peptide-protected Au NCs using CO as the reducing agent. (a–d) are 
reprinted with permission from Ref 22. Copyright 2012 American Chemical 
Society. (e) is reprinted with permission from Ref 78. Copyright 2013 American 
Chemical Society. 
 
The instability of the non-thiolate coordinated Au(I) complex intermediates 
can also be exploited to create a mild reducing environment for synthesizing 
highly luminescent peptide-protected Au NCs. Recently, we developed a facile 
synthesis of ultrabright GSH-protected Au NCs (QY ~ 15%) by mixing aqueous 
solutions of HAuCl4 and GSH (GSH-to-Au ratio = 1.5:1) and heating the 
reaction mixture at 70 °C for 24 h.66 The relatively unstable non-thiolate 
coordinated Au(I) complex intermediates [Au(I)–X complexes in Scheme 2.8] 
in the reaction could undergo a disproportionation reaction to form Au(0) and 
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Au(III) in aqueous solution under heating. The resultant Au(III) could be 
reduced to form unstable non-thiolate coordinated Au(I) complexes again by 
various reducing agents in the reaction mixture (e.g., thiol and disulfide groups), 
thereby accumulating Au(0) atoms that are part of the resultant NCs. As 
illustrated in Scheme 2.8, we utilized the mild reduction environment created 
by the insufficient thiolate ligands and heating to preserve the oligomeric 
complexes and condense them onto the in situ generated Au(0) cores to form 
GSH-protected Au NCs [Au(0)@Au(I)–thiolate NCs] with an emission 
originated from the aggregation-induced emission (AIE) of the complexes on 
the NC surface. The resultant GSH-protected Au NCs consisted of five major 
sizes (from 29 to 43 Au atoms) as characterized by PAGE separation and ESI-
MS. These Au NCs showed much higher content of Au(I)–thiolate complexes 
in their structure as compared with conventional thiolate-protected Au NCs with 
a similar number of Au atoms. This synthesis approach can be readily extended 




Scheme 2.8 Schematic illustration of the synthesis of highly luminescent 
GSH-protected Au NCs using the mild reducing environment created by both 




2.3.2.3 Surface functionalization of Au/Ag NCs 
The surface functionalization of protein- and peptide-protected Au/Ag NCs are 
pivotal for the rational design of NCs for actual biomedical applications. There 
are two major approaches to realize the surface functionalization of the NCs, 
that is, ligand design and post-synthesis modification. 
Designing cysteine-containing peptide ligands for metal NC synthesis has 
opened exciting opportunities in fabricating peptide-protected Au NCs with 
specific biological activities. Short custom-designed peptides can be readily 
obtained thanks to the advancement of the chemical synthesis of peptides. For 
example, Cui et al. demonstrated syntheses of luminescent peptide-protected Ag 
NCs using a custom-designed peptide with the amino acid sequence 
CCYRGRKKRRQRRR or CCYTAT, which contains a nucleus localization 
signal sequence (TAT) and could impart the cell-targeting capability to the 
resultant peptide-protected Ag NCs.79 Our group also demonstrated the usage 
of custom-designed tripeptides with the general formula Am-Cys-Am, where 
Am is an amino acid residue with desired functionalities, for the synthesis of 
luminescent metal NCs using different synthetic approaches.66, 71  
Post-synthesis modifications of the NC surface are routinely carried out 
using bioconjugation chemistry to covalently attach desired functional moieties 
onto the ligand shell of the NCs. For examples, Retnakumari et al. conjugated 
folic acid (FA) with BSA-protected Au NCs using the well-known carbodimide 
cross-linker [e.g., 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide, EDC]. 
The small FA moieties were able to retain their receptor binding affinity after 
conjugated to the NCs and were able to target the cancer cells that over-express 
the folate receptor.29 Similarly, the surface of peptide-protected metal NCs can 
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also be functionalized through post-synthesis modification. For example, 
Muhammed et al. conjugated red-emitting GSH-protected Au23 NCs with 
streptavidin, which could bind biotin strongly. The interaction of streptavidin 
and biotin allowed the modified Au NCs enter HepG2 cells (human 
hepatocellular carcinoma cells, which contained large amount of biotin) 
efficiently via the receptor-mediated uptake.80 
 
 
2.4 Potential biomedical applications of protein- and peptide-
protected Au/Ag NCs 
The unique physicochemical properties (e.g., strong photoluminescence and x-
ray absorption) and biological activities (e.g., antimicrobial and tumor 
targeting) of protein- and peptide-protected Au/Ag NCs in combination with the 
good biocompatibility imparted by the biogenic shell of the NCs have allowed 
the NCs to become an ideal platform for developing optical probes for 
bioimaging and biosensing, and constructing antimicrobial and therapeutic 
agents. We will highlight some examples in this section. 
 
2.4.1 Bioimaging 
The current fluorescent probes for biological imaging suffer from relatively 
low photostability (e.g., organic dyes) and potential toxicity (e.g., 
semiconductor quantum dots). Luminescent noble metal NCs, in particular the 
protein- and peptide-protected Au NCs, have become an emerging class of 
optical probes for both in vitro (e.g., cell imaging) and in vivo (e.g., tumor 
imaging) biological imaging because of their extraordinary chemical stability, 
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good photostability, inherent biocompatibility (e.g., good water solubility and 
low toxicity), and tunable physicochemical properties and bioactivities. The 
luminescence of the Au/Ag NCs has attracted great interests, and the 
understanding of their luminescence properties is essential for improving the 
design and synthesis of the NCs for strong and tunable emission and developing 
new applications.3, 81, 82 The source of the luminescence of Au/Ag NCs has been 
widely attributed to the fluorescence from the discrete electronic transitions of 
their metallic cores.83 However, phosphorescence originated from ligand-to-
metal charge transfer (LMCT) could contribute significantly to the 
luminescence of thiolate-protected Au NCs.84 In addition, the phosphorescence 
resulted from the aggregation-induced emission of the oligomeric Au(I)–
thiolate motifs condensed on the NC surface may dominate the luminescence of 
thiolate-protected Au NCs.66 Besides the source of luminescence, other 
fundamental aspects of the luminescence properties of Au/Ag NCs, such as size 
and structure effects on luminescence and critical factors that affects QYs, are 
still not well understood. 
Far-red- or near-IR-emitting Protein- and peptide-protected Au NCs could 
be directly used for in vivo fluorescence imaging to study the pharmacokinetics 
of the NCs, including their passive tumor targeting capability and renal 
clearance.26, 85, 86 For example, Wu et al. first demonstrated the possibility of 
using the red-emitting BSA-protected Au NCs (hydrodynamic diameter (HD) ~ 
2.7 nm) for tumor imaging.87 The luminescence of the Au NCs (with an 
emission wavelength of 710 nm) was easily separated from the autofluorescence 
of the body by spectral unmixing, and the high photostability of the NCs 
(comparable to QDs) permitted a whole body real-time in vivo imaging. Au 
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NCs were found to have longer circulation time than PEGylated nanomaterials 
and could be cleared by kidney. They also showed accumulation in tumors of 
two different tumor models (Scheme 2.9 shows the accumulation of Au NCs in 
a MDA-MB-45 tumor model), indicating their passive tumor targeting ability 
via the enhanced permeability and retention (EPR) effect. Moreover, those mice 
injected with the NCs showed only slight weight loss after four weeks and no 
sign of acute or long toxic effects. Zheng’s group also used fluorescence 
imaging to first show that near-IR-emitting GSH-protected ultrasmall Au NPs 
(GS-AuNPs) with a hydrodynamic diameter of 3.0 ± 0.4 nm and an emission 
peak at 810 nm have efficient renal clearance in mice.86 They further 
demonstrated that the NPs behave like small organic dye molecules (e.g., IRDye 
800CW) but with a much longer tumor retention time and faster normal tissue 
clearance as compared to those of IRDye 800CW (Scheme 2.10), which allows 
more rapid detection of tumor and less accumulation in reticuloendothelial 
system.26 Their results also suggest that the EPR effect is also applicable for 





Scheme 2.9 (a) In vivo fluorescence images showing significant passive 
tumor accumulation (via EPR effect)  of iv-injected BSA-protected Au NCs 
(HD ~ 2.7 nm) in a MDA-MB-45 tumor-bearing mice. The tumor areas are 
indicated with arrows. (b) Ex vivo fluorescence image of the tumor and muscle 
tissue around the tumor from the mice used in (a). Reproduced from Ref 87 with 





Scheme 2.10 (a) In vivo fluorescence images of MCF-7 tumor-bearing mice 
iv-injected with GS-AuNPs and IRDye 800CW. The tumor areas are indicated 
with arrows. (b and c) Ex vivo fluorescence images of organs and tumors 
removed from MCF-7 tumor-bearing mice iv-injected with (b) GS-AuNPs and 
(c) IRDye 800CW. Labels: 1 - tumor; 2 - liver; 3 - lung; 4 - spleen; 5 - heart; 6 
- kidney (left) and 7 - kidney (right). Reprinted with permission from Ref 26. 
Copyright 2012 American Chemical Society. 
 
Besides the capability of passively targeting tumors by EPR effect, the 
protein- and peptide-protected Au NCs could also be conjugated with active 
targeting moieties that can enable active cell internalization and tissue targeting. 
For example, Retnakumari et al. conjugated BSA-protected Au NCs (λem, max = 
674 nm, QY ~ 6%) with folic acid (FA) through a coupling reaction between 
the gamma-carboxyl group of FA and the amine groups on the surface of BSA.29 
In this way, the folic acid retained its receptor (FR) binding affinity, and the 
NCs only suffered a marginal reduction in QY (QY ~ 5.7%). The FA-
conjugated NCs were non-toxic as suggested by reactive oxygen species (ROS) 
analysis and were able to specifically stain or detect the FR+ve nasopharyngeal 
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carcinoma cells (KB) by FR-mediated endocytosis while leaving the FR-ve and 
FR-depressed cells unstained. Similarly, Chen et al. constructed a 
biocompatible theranostic nanocomposite that contains a GSH-protected Au NC 
(λem, max = 610 nm) conjugated with a FA-modified pH-responsive amphiphilic 
polymer for controlled drug release.88 The nanocomposite could encapsulate 
hydrophobic drugs (e.g., paclitaxel, PTX) and release them in mildly acidic 
conditions (e.g., in lysosomes). Therefore, the assembled nanocomposites were 
able to simultaneously provide targeting, imaging, and anticancer therapy 
functionalities. Both in vitro and in vivo (Scheme 2.11) studies confirmed the 
active tumor targeting capability of this theranostic composite. 
 
 
Scheme 2.11 Luminescence intensities of the dissected organs of sacrificed 
mice bearing the HeLa tumor at 24-h after the intravenous injection of PTX-
loaded nanocomposite with (L-AuNCs/FA-PDNH) or without (L-
AuNCs/PDNH) FA conjugation. Reprinted with permission from Ref 88. 
Copyright 2013 Wiley-VCH. 
 
Besides using the photoluminescence of the Au NCs for biological imaging, 
other imaging methods such as X-ray computed tomography (CT) that utilize 
the strong X-ray absorption of the Au atoms and single-photon emission 
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computed tomography that utilizing radioactive isotope of Au (e.g., 198Au) can 
also be used.39, 85, 86, 89 
 
2.4.2 Biosensing 
The optical properties of the protein- and peptide-protected Au/Ag NCs, 
particularly the photoluminescence of the NCs, have enabled the Au/Ag NCs as 
an emerging class of optical probes for sensing chemicals that are hazardous or 
important for biological systems (e.g., Hg2+, Cu2+, Pb2+, CN-, and glucose)30, 34, 
90-97 and biomolecules (e.g., biothiols and proteins)98, 99. For example, Xie et al. 
first demonstrated the highly sensitive (with a limit of detection of about 5 nM 
or 0.1 ppb) and selective detection of Hg2+ based on the luminescence 
quenching of red-emitting BSA-protected Au NCs by Hg2+.27 The luminescence 
quenching was attributed to the specific and strong metallophilic Hg2+···Au+ 
interactions, which endowed the high selectivity and sensitivity of this detection 
method. 
As a result of the high stability and strong luminescence of the BSA-protected 
Au NCs and the simplicity, fast response, and high performance of the detection 
method, miniaturized devices such as paper test strip could be easily developed 
for sensing Hg2+ with a high sensitivity (e.g., 2 ppb, which could meet the 
requirement set by the United State Environmental Protection Agency). Pu et al. 
studied the efficient fluorescence resonance energy transfer (FRET) between 
the blue-emitting cationic-oligofluoroene-substituted polyhedral oligomeric 
silsesquioxane (POSSFF) and the red-emitting BSA-protected Au NCs. 
Subsequently, they developed an efficient multicolor probe that was formed by 
the electrostatic attractions between POSSFF and the Au NCs and successfully 
applied it for visual detection and intracellular sensing of Hg2+.28 
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Cys plays vital roles in reversible redox reaction in biological systems, and 
Cys deficiency can cause slowed growth, hair depigmentation, edema, and liver 
damage. In addition, Cys is also a potential neurotoxin. The facile analysis of 
Cys levels is pivotal for early diagnosis of Cys-related diseases. Yuan et al. 
developed a simple Cys sensor based on the quenching of red-emitting GSH-
protected Ag NCs.98 The GSH-protected Ag NCs showed extremely high 
sensitivity for Cys (limit of detection < 3 nm) because of the ultrasmall size of 
the Ag NCs and the high affinity of the thiol–Ag interaction. The Ag NCs also 
exhibited high selectivity against nonthiol-containing amino acids as a result of 
the specific and strong thiol-Ag interaction. Interestingly, the Ag NCs could 
also be used to differentiate Cys from GSH or other sterically bulkier thiols. 
This was attributed to the steric hindrance of the organic shell (GSH ligands) of 
the NCs, which only allows thiols smaller than GSH to interact with the core of 




The antimicrobial activity of the protein- and peptide-protected Au/Ag NCs 
could be imparted either by the ligand shell or the metal core or both. For 
example, lysozymes are glycoside hydrolases that can damage bacterial cell 
walls by attacking the peptidoglycans (especially abundant in Gram-positive 
bacteria). Chen et al. synthesized lysozyme-protected Au NCs and 
demonstrated that the bioactivity of the lysozyme on the NCs was retained.46 
The lysozyme-protected Au NCs was used to inhibit the growth of the 
antibiotic-resistant bacteria, such as pan-drug-resistant Acinetobacter 
baumannii and vancomycin-resistant Enterococcus faecalis. Inspired by the 
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wide success of Ag NPs as antimicrobial agents, Yuan et al. developed 
luminescent GSH-protected Ag NCs via a cyclic reduction-decomposition 
process and first investigated the antimicrobial activity of the Ag NCs, which 
showed superior bactericidal properties against Pseudomonas aeruginosa.72 
These ultrafine luminescent Ag NCs could be further developed as an emerging 
class of high-efficiency antimicrobial agent. However, further studies on the 
toxicity of the Ag NCs are required for developing more biocompatible 
antimicrobial Ag NCs. 
 
2.4.4 Radiotherapy sensitization 
Protein- and peptide-protected Au NCs could also be a new type of radiotherapy 
sensitizer. Among the current radiosensitizer materials [e.g., carbon (Z = 6), 
iodine (Z = 53), and gadolinium (Z = 64)], gold is currently unmatched in terms 
of radiotherapy enhancement efficiency due to its large atomic number (Z = 79), 
which is directly related to the ability of the material to interact with the incident 
radiation to generate secondary radiations and electrons. In addition, protein- 
and peptide-protected Au NCs has excellent biocompatibility and passive tumor 
targeting capability. The tumor targeting could be enhanced even further by 
conjugating targeting moieties to the NCs. Recently, Zhang et al. explored the 
radiotherapy sensitizing effect of both BSA- and GSH-protected Au25 NCs.
100 
They found that the GSH-protected Au25 NCs were able to preferentially 
accumulate in tumor via EPR effect and strongly enhanced the cancer 






As discussed above, to ensure the biocompatibility and renal clearance of 
Au/Ag NCs, biomolecules, proteins and peptides in particular, have been widely 
employed as the ligands for the synthesis of the NCs. The biomineralization-
inspired syntheses of protein-protected Au/Ag NCs have been shown to be very 
facile, robust and versatile and are able to synthesize NCs protected by different 
types of proteins at large scale. In addition, as a result of the mildness of the 
synthetic conditions and the ultrasmall size of the resultant Au/Ag NCs, the 
bioactivity of the protein can be preserved during or after the syntheses, which 
opens up many possibilities of using these protein-protected NCs as artificial 
proteins for theranostic applications. The syntheses of peptide-protected Au/Ag 
NCs are similar to the synthetic approaches developed for water-soluble 
thiolate-protected Au/Ag NCs, and are capable of producing highly 
monodisperse (or atomically precise) and highly luminescent NCs, which could 
allow quantitative and precise characterization of the interaction between the 
peptide-protected NCs and the biological systems. In addition, the advancement 
of chemical synthesis of peptides allows the use of rational design of peptides 
with different functionalities for NC synthesis, which would allow the tailoring 
of the surface of the resultant NCs for theranostic applications. In addition, the 
surface of the protein- and peptide-protected Au/Ag NCs can be readily 
modified with functional moieties via post-synthesis modification using 
common bioconjugation chemistry. Lastly, the unique physicochemical 
properties (e.g., strong photoluminescence and x-ray absorption) and biological 
activities (e.g., antimicrobial and tumor targeting) of the protein- and peptide-
protected Au/Ag NCs have allowed them to show great potential as optical 
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probes for bioimaging and biosensing, efficient antimicrobial agents, and 
therapeutic agents. With continued experimental efforts and fundamental 
understandings of the interfacing of as-designed protein and peptide-protected 
Au/Ag NCs and the biological systems at both cellular and animal level, the 
potentials of Au/Ag NCs for biomedical applications can be largely realized, 
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CHAPTER 3    
From the Aggregation-Induced-Emission of Au(I)–thiolate 
Complexes to Ultra-Bright Au(0)@Au(I)–thiolate Core-
Shell Nanoclusters 
3.1 Introduction  
Thiolate-protected gold nanoclusters (Au-thiolate NCs for short) are ultrasmall 
(< 2 nm) nanoparticles stabilized by thiolate ligands.1, 2 The recent interest in 
this subgenre of nanoparticles is due to their significance in basic and applied 
research (e.g., as the missing link between atoms and nanocrystals,1-4 and the 
utilization of their molecular-like properties such as quantized charging5-8 and 
luminescence9-13 for application developments). The most interesting feature of 
Au-thiolate NCs is their luminescence properties. Luminescent Au-thiolate 
NCs, which combine strong luminescence with low toxicity, ultrafine size, and 
good biocompatibility are ideal bioimaging and theranostic probes14-16 only if 
they can be synthesized by general and convenient methods. 
Au-thiolate NCs are commonly prepared bottom-up by the reaction between 
Au(I)–thiolate complexes and a strong reducing agent – sodium borohydride 
(NaBH4).
17-20 While the resulting Au-thiolate NCs show luminescence in the 
blue to near-infrared region, their quantum yield (QY) rarely exceeds 0.1%.1 
Recent studies have shown that strongly luminescent Au-thiolate NCs can also 
be produced by a top-down approach via the decomposition of large Au 
nanocrystals (>2 nm)21 or large Au(I)–thiolate complexes (~120 nm).22 
However, the decomposition kinetics is slow, requiring a very long time for 
reaction completion (e.g., 2 weeks for the decomposition of large Au(I)–thiolate 
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complexes). There is also the onerous post-treatment to separate the NCs from 
incompletely decomposed reaction intermediates.  
Understanding the origin of luminescence in Au-thiolate NCs can improve 
the design and synthesis for strong luminescence. However, several issues 
fundamental to the luminescence of Au-thiolate NCs such as the source of 
emission (e.g., whether it is from the Au atoms in the core or Au atoms on the 
NC surface), the size effect in luminescence, and the critical factors in QY, are 
still presently not well understood.1 Since almost all Au-thiolate NCs are formed 
by the reduction of Au(I)–thiolate complexes, a careful study of Au(I)–thiolate 
complexes can provide new insights for a better understanding of the 
luminescence properties of Au-thiolate NCs. 
This chapter is an account of our investigation of Au(I)–thiolate complexes. 
The most important finding is the discovery of the mechanism of aggregation-
induced emission (AIE),23 i.e., non-luminescent oligomeric Au(I)–thiolate 
complexes can generate very strong luminescence upon aggregation, with 
intensity and color of the luminescence dependent on the degree of aggregation. 
The AIE discovery was then used to design highly luminescent Au-thiolate NCs 
and their synthesis by a facile one-pot procedure. Specifically these are core-
shell structured Au(0)@Au(I)–thiolate NCs (hereafter referred to as 
Au(0)@Au(I)–thiolate NCs) formed by the aggregation of Au(I)–thiolate 
complexes and in-situ generated atomic Au species. The Au NCs synthesized 
as such have a high content of Au(I)–thiolate complexes in the shell of the core-
shell nanostructure, which give rise to the strong luminescence of the NCs. The 
versatility and general utility of the procedures was then demonstrated by the 
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3.2 Experimental section 
Chemicals. All chemicals were commercially available and used without 
further purification. L-glutathione in the reduced form (GSH) and 2,5-
dihydroxybenzoic acid (DHB) were obtained from Sigma-Aldrich. Hydrogen 
tetrachloroaurate trihydrate (HAuCl4·3H2O) was provided by Alfa Aesar. 
Custom-designed tri-peptides including Glu-Cys-Glu, Ser-Cys-Ser, and His-
Cys-His were supplied by GL Biochem Ltd. (Shanghai, China). Ultrapure water 
(Milli-Q®) with a resistivity of 18.2 MΩ was used as the general solvent 
throughout the study. 
Synthesis of Oligomeric Au(I)–thiolate Complexes. Freshly prepared 
aqueous solutions of HAuCl4 (20 mM, 0.50 mL) and GSH (100 mM, 0.20 mL) 
were mixed with 4.30 mL of ultrapure water under gentle stirring (500 rpm) at 
25 °C for 5 min. A precipitate was formed. NaOH (0.5 M) was then added to 
the mixture to bring the pH to ~7.0. The precipitate was dissolved within 
seconds, and the solution was aged for ~ 1 h. The oligomeric Au(I)–thiolate 
complexes formed as such were used without purification and could be stored 
at 4 °C for 3 months without any changes. 
Synthesis of Luminescent Au-Thiolate NCs. Freshly prepared aqueous 
solutions of HAuCl4 (20 mM, 0.50 mL) and GSH (100 mM, 0.15 mL) were 
mixed with 4.35 mL of ultrapure water at 25 °C. The reaction mixture was 
heated to 70 °C under gentle stirring (500 rpm) for 24 h. An aqueous solution 
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of strong orange-emitting Au NCs was formed. The orange-emitting Au NC 
solution could be stored at 4 °C for 6 months with negligible changes in their 
optical properties. The synthesis of luminescent Au NCs protected by other 
thiolate-containing tri-peptides was carried out under similar conditions except 
for the replacement of GSH by other tri-peptides. 
Materials Characterization. UV–vis absorption and photoluminescence 
(PL) spectra were recorded by a Shimadzu UV-1800 photospectrometer and a 
PerkinElmer LS-55 fluorescence spectrometer, respectively. 
Photoluminescence lifetimes were measured by time-correlated single photon 
counting (TCSPC) using a HORIBA Jobin Yvon Fluorolog-3 
spectrofluorometer with a pulsed LED (344 nm, pulse duration < 1 ns) as the 
excitation source. The size of the aggregates of Au(I)–thiolate complexes was 
measured by dynamic light scattering (DLS) on a Malvern Zetasizer Nano ZS. 
TEM images of NCs were taken on a JEOL JEM 2010 microscope operating at 
200 kV. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrometry was carried out on a Bruker Daltonics Autoflex II 
MALDI TOF/TOF system. A Bruker MicroTOF-Q ESI time-of-flight system 
operating in the negative ion mode (sample injection rate: 120 μL∙min−1; 
capillary voltage: 4 kV; nebulizer: 1.5 bar; dry gas: 4 L∙min−1 at 160 °C; and 
m/z 1000−6000) was used for electrospray ionization mass spectrometry (ESI-
MS). X-ray photoelectron spectroscopy (XPS) measurements were performed 
on a VG ESCALAB MKII spectrometer. The yield of luminescent Au-thiolate 
NCs based on the Au atoms in the starting mixture was calculated from 
inductively coupled plasma mass spectrometry (ICP-MS) measurements on an 
Agilent 7500A. Thermogravimetric analysis (TGA) was conducted on a 
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Shimadzu TGA-60 analyzer under N2 atmosphere (flow rate of 100 mL·min
−1). 
Native polyacrylamide gel electrophoresis (PAGE)3, 18, 24, 25 was carried out on 
a BIO-RAD Mini-PROTEAN Tetra Cell system using discontinuous gels (1.0 
× 83 × 73 mm). Stacking and resolving gels were prepared from 4 and 30 wt% 
of acrylamide monomers respectively. For analytical gels (10-well), sample 
solutions (10 µL of Au NCs with 1.4 mM Au in 6 vol% glycerol) were loaded 
into the wells of the stacking gel. For preparative gels (5-well), sample solutions 
(20 µL of Au NCs with ~20 mM Au in 6 vol% glycerol) were loaded into the 
wells. The electrophoresis was allowed to run for ~2.5 h at a fixed voltage of 
200 V at 4 °C. 
 
 
3.3 Results and discussion 
3.3.1 Aggregation-induced emission of Au(I)–thiolate complexes 
In this study, a natural tri-peptide, glutathione (GSH or H-SG = γ-Glu-Cys-Gly), 
was used as the model thiolate ligand for the synthesis of oligomeric Au(I)–
thiolate complexes. The complexes were formed by mixing aqueous solutions 
of GSH and HAuCl4 at 25 °C for 5 min, followed by NaOH addition to bring 
the pH of the mixture to ~7.0 and aging for ~1 h. The formation of the 
complexes involved two steps. The first step was the reduction of Au(III) to 
Au(I) by GSH,17, 26, 27 followed immediately by the coordination of Au(I) to the 
thiol group to form insoluble aggregates of Au(I)–thiolate complexes. The 
second step, which was initiated by the addition of NaOH, was the dissolution 
of the aggregates and the oligomerization of Au(I)–thiolate complexes. The 
negative charge on the GSH (iso-electric point of pH 2.85)28 at pH 7.0 imparts 
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good water solubility to the complexes. The resultant reaction mixture was clear 
and colorless (inset of Figure 3.1a, item 1) with two distinct absorption peaks at 
330 and 375 nm in the UV–vis region (Figure 3.1a). The locations of these peaks 
are a good match for the Au10–12SG10–12 species reported by Negishi et al.
3 The 
small size of the Au(I)–thiolate complexes was substantiated by MALDI-TOF 
mass spectrometry where the largest species in the raw product was [Au12SG11]
+ 
(Figure 3.1b). Native PAGE (30%) analyses provided yet another evidence for 
the small size of the complexes: there was only one dark band under UV 





Figure 3.1 (a) UV–vis absorption spectrum and (b) MALDI-TOF mass 
spectrum of oligomeric Au(I)–thiolate complexes. The inset in (a) shows the 






Figure 3.2 PAGE results for (a) AumSGn NCs reported by Negishi et al.
3 
(under visible light), (b) the as-synthesized Au(0)@Au(I)–thiolate NCs (under 
UV light), and (c) the oligomeric Au(I)–thiolate complexes (under UV light). 
The table shows the molecular formula of Au NCs in outlined bands in (a) and 
(c). 
 
The oligomeric Au(I)–thiolate complexes in aqueous solution were not 
luminescent under UV light (inset of Figure 3.1a, item 2). However, the 
complexes upon aggregation generated strong luminescence, as shown in the 
insets of Figure 3.3. Such aggregation-induced emission (AIE) phenomenon has 
recently been observed in luminophore systems involving organic, 
organometallic and polymeric luminogens.23 The aggregation of oligomeric 
Au(I)–thiolate complexes was induced by two different approaches: solvent-
induced aggregation and cation-induced aggregation. The solvent-induced 
aggregation method made use of a weakly polar solvent – ethanol (dielectric 
constant of ~25.3),29 to destabilize the complexes in water (dielectric constant 
of ~80.1).30 The addition of a high concentration of ethanol (e.g., 95% by 
volume) in water disrupted the hydration shell of Au(I)–thiolate complexes, 
resulting in charge neutralization and consequent aggregation of the complexes. 
The aggregation of Au(I)–thiolate complexes also promoted intra- and inter-
complex aurophilic interactions between the closed-shell metal centers (5d10 for 
Au(I)). The Au(I)∙∙∙Au(I) interaction is greatly magnified by relativistic effects, 
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and has a typical bond energy of 29 to 46 kJ∙mol-1 which is comparable to that 
of a hydrogen bond.31, 32 The formation of aurophilic bonds in turn provided the 
impetus for aggregation, and denser and more rigid aggregates were formed. 
The cation-induced aggregation method, on the other hand, exploited the 
high affinity of electrostatic and coordination interactions33 between certain 
multivalent cations (e.g., Cd2+) and the monovalent carboxylic anions (from 
GSH) in the complexes to form inter- and/or intra-complex cross-links. Besides 
neutralizing the negative charge on the complexes, the cross-linkers also 
brought the Au(I)–thiolate complexes closer and facilitated the formation of 
aurophilic bonds and dense aggregates. 
The UV–vis absorption spectra of both solvent-induced (Figure 3.3a, solid 
blue line) and cation-induced (Figure 3.3b, solid blue line) aggregates bear a 
strong resemblance to the spectrum of oligomeric Au(I)–thiolate complexes 
(Figure 3.1a). The stronger background scattering at wavelengths < 600 nm was 
due to the larger size of the aggregates. The strong Rayleigh scattering of a red 
laser pointer beam by a dispersion of the aggregates (Figure 3.4b and c) versus 
no visible Rayleigh scattering by the solution of oligomeric Au(I)–thiolate 
complexes (Figure 3.4a), is another proof of the existence of large aggregates. 
The photoemission spectra (Figure 3.3, solid red lines) of the aggregates 
exhibited two peaks at 565 and 610 nm. The aggregates showed a broad 
excitation band (Figure 3.3, dotted red lines) with two shoulder peaks at 330 
and 375 nm in correspondence with their two absorption peaks (Figure 3.3, solid 
blue lines). The large Stokes shift (> 200 nm) suggests that the emission from 
aggregated Au(I)–thiolate complexes was mainly phosphorescence. This was 
also supported by luminescence lifetime measurements. Analysis of the 
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luminescence decay response confirmed the predominance of microsecond 
lifetime components in the aggregated Au(I)–thiolate complexes (Figure 3.5 
and Table 3.1: 2.93 µs (85%) and 0.455 µs (14%) for the ethanol-induced 
aggregates; and 2.41 µs (79%) and 0.355 µs (18%) for the Cd2+-induced 
aggregates). The emission from the aggregates could be attributed to ligand-to-
metal charge transfer (LMCT) or ligand-to-metal-metal charge transfer 
(LMMCT) from the sulfur atom in the thiolate ligands to the Au atoms, and 




Figure 3.3 UV–vis absorption (solid blue lines), photoemission (solid red 
lines, λex = 365 nm) and photoexcitation (dotted red lines, λem = 610 nm) spectra 
of Au(I)–thiolate complexes aggregated by (a) ethanol (95% of ethanol by 
volume) and (b) Cd2+ ions (with Cd2+-to-GSH ratio of 1:2). The insets show the 




Figure 3.4 Digital photos of (a) the oligomeric Au(I)–thiolate complexes, 
and the aggregated complexes induced by (b) ethanol (95% of ethanol by 
volume) and (c) Cd2+ ions (with Cd2+-to-GSH ratio of 1:2). Cuvettes in (a) to (c) 
were irradiated by a red laser beam. The test setup for the Rayleigh scattering is 





Figure 3.5 Photoluminescence decay profiles of Au(I)-SG complexes 
aggregated by (a) ethanol (95% of ethanol by volume) and (b) Cd2+ ions (with 
Cd2+-to-GSH ratio of 1:2), and (c) the as-synthesized luminescent Au NCs in 
water. The upper portion of each image is an exponential fit of the experimental 
data, and the lower portion of each image shows the residuals of fitting. 
 
Table 3.1 Summary of lifetimes of the aggregated Au(I)-SG complexes 











































  * Lifetimes of the scattered light from the aggregated complexes. 
 
The dependence of luminescence properties on the aggregation degree of 
Au(I)–thiolate complexes was examined using the aggregates from solvent-
induced aggregation. As illustrated in Figure 3.6a, the aggregation degree was 
controlled by the polarity of the mixed solvent which could be varied by the 
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volume fraction of ethanol in the solvent fe =Volethanol/Volethanol+water. Increasing 
fe increased the aggregation and formed denser and smaller aggregates. Figure 
3.6b (top row) shows that the complex solution was clear and non-luminescent 
until fe was 75%, at which time the solution turned cloudy with very weak red 
emission due to the incipient formation of aggregates. Increasing the fe to 95% 
re-clarified the solution, suggesting the presence of well-dispersed colloids of 
denser and smaller aggregates, which was also supported by the DLS 
measurements of the complex solutions with fe from 75 to 95% (Figure 3.7). 




Figure 3.6 (a) Schematic illustration of the solvent-induced AIE properties 
of oligomeric Au(I)–thiolate complexes. (b) Digital photos of Au(I)–thiolate 
complexes in mixed solvents of ethanol and water with different fe under visible 
(top row) and UV (bottom row) light. (c) UV–vis absorption and (d) 
photoemission spectra of Au(I)–thiolate complexes in mixed solvents with 
different fe. The inset in (d) shows the relationship between the luminescence 





Figure 3.7 The average sizes of the aggregates of oligomeric Au(I)-SG 
complexes at different fe (Volethanol/Volethanol+water) measured using dynamic light 
scattering (DLS). 
 
UV–vis spectroscopy (Figure 3.6c) was used to follow the aggregation 
degree of complexes with the increase in fe. The clouding of the reaction mixture 
at 75% fe also caused a sudden hyperchromic shift (Figure 3.6c, dotted black 
arrow) of the UV–vis absorption spectrum due to the large increase in 
background scattering. When fe was increased further from 75 to 95%, the 
formation of smaller and denser aggregates was suggested by hypochromic 
shifts of the spectrum (Figure 3.6c, dotted blue arrow). Photoemission spectra 
(Figure 3.6d) were also recorded to analyze the emission changes due to 
variations in aggregation degree. After a fe value of 75%, the luminescence 
intensity increased monotonically with the increase in aggregation degree (inset 
of Figure 3.6d). The main peak in the emission spectrum also shifted from 630 
(red-emitting) to 565 nm (yellow-emitting) with the increase in fe. In addition, 
the vacuum-dried oligomeric Au(I)–thiolate complexes in the solid state, as an 
extreme form of dense aggregation, also exhibited strong yellow emission 
(Figure 3.8). The solvent-induced AIE of the oligomeric Au(I)–thiolate 
complexes was reversible since decreasing fe could re-dissolve the aggregates, 
thereby annulling the AIE mechanism and subsequently quenching the 





Figure 3.8 Digital photos of the oligomeric Au(I)–thiolate complexes in the solid 
state (vacuum-dried) under visible (item 1) and UV (item 2) light. 
 
Some inference about the AIE of Au(I)–thiolate complexes can be made 
from the above observations, especially the relation between luminescence 
intensity and the degree of aggregation: (1) increasing the degree of aggregation 
increased the intra- and inter-complex aurophilic Au(I)···Au(I) interactions and 
consequently the luminescence intensity of the complexes;31, 35, 41 and (2) 
stronger inter- and intra-complex interactions (e.g., van der Waals force and the 
aurophilic interactions) due to aggregation increased the restraints on the 
intramolecular vibrations and rotations of the complexes; the probability of non-
radiative relaxation of the excited states was reduced as a result and this 
enhanced the luminescence further.23, 42 Hence, dense aggregates generated 
more intense luminescence because of their stronger aurophilic Au(I)···Au(I) 
interactions and more restrained molecular vibrations. However, it is still 
unclear how the increase in the aggregation degree led to the observed blue shift 
in luminescence (Figure 3.6d). One possible explanation is that, with the 
increase in the aggregation degree, inter-complex aurophilic interactions 
predominated over intra-complex aurophilic interactions.43 The longer 
Au(I)···Au(I) distance in inter-complex aurophilic interactions therefore led to 
a higher emission energy (or shorter emission wavelength).35, 44 
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While the aggregation of Au(I)–thiolate complexes could generate strong 
luminescence, the aggregates were large, poly-dispersed and hence easily salted 
out from the solution. Such propensities limited their usability as practical 
luminescence probes. However, the discovery of the AIE properties of Au(I)–
thiolate complexes has enabled us to develop a novel synthetic route to 
synthesize highly luminescent Au-thiolate NCs in water. 
 
3.3.2 Synthesis of highly luminescent Au-thiolate NCs 
The key strategy in our synthesis of highly luminescent Au-thiolate NCs was to 
condense the Au(I)–thiolate complexes into a compact shell on an in-situ 
generated Au(0) core. The core-shell construction and the small size of the NCs 
imparted stability and good solubility in water due to the charge and steric 
stabilization effects of the GSH ligands in the shell. GSH was the reducing cum 
protecting agent in the synthesis and reaction temperature was used to vary its 
dual functionality. The protection of Au(I)–thiolate complexes from reduction 
in the process and the control of their aggregation on the Au(0) surface were 
crucial to the formation of highly luminescent Au-thiolate NCs. In a typical 
synthesis, aqueous solutions of HAuCl4 and GSH (thiolate ligands) were mixed 
and allowed to react under gentle stirring at an elevated temperature of 70 °C 
for 24 h. The reaction mixture changed from yellow to colorless within minutes, 
and then turned to light-yellow slowly. The typical yield of luminescent Au-
thiolate NCs based on the amount of Au atoms in the starting mixture was ~ 90% 
according to ICP-MS measurements. 
Figure 3.9 is a postulation of the formation of highly luminescent Au-thiolate 
NCs in three stages. The first stage was the reduction of Au(III) to Au(I) by the 
thiol group of GSH (or the disulfide group from the resultant oxidized GSH 
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(GS-SG)17, 26, 27); and the immediate coordination of Au(I) to the thiol group of 
GSH to form Au(I)–thiolate complexes, or to other functional groups in GSH 
(e.g., the carboxyl groups) or small anions in the solution (e.g., chloride) to form 
Au(I)-X complexes (X represents any non-thiolate ligand, Figure 3.9). The 
second stage was the selective reduction of Au(I)-X complexes to Au(0) atoms 
and subsequent sequestration of the Au(0) species by Au(I)–thiolate complexes 
due to the high affinity between Au(0) atoms and Au(I).45 Au(0)-on-Au(I)–
thiolate intermediates were formed as a result (Figure 3.9). The reduction of 
Au(I)-X complexes to Au(0) by the disulfide group of the resultant GS-SG (see 
Figure 3.10 and the detailed discussion) was made more facile by the favorable 
reduction kinetics at the elevated temperature of 70 °C. The selectivity of Au(I)-
X complexes over Au(I)–thiolate complexes in reduction could be explained by 
the more positive redox potentials of the former – a consequence of the weaker 
binding (between Au(I) and X) in Au(I)-X than in Au(I)–thiolate. The third 
stage was the slow aggregation of Au(0)-on-Au(I)–thiolate intermediates by 
collision and fusion of Au(0) atoms into a Au(0)-core and Au(I)–thiolate-
complex-shell structure. The Au(0)@Au(I)–thiolate NCs synthesized as such 
had a high content of compact aggregates of Au(I)–thiolate complexes in the 
shell of the core-shell nanostructure. Very strong luminescence was emitted by 





Figure 3.9 Schematic of the synthesis of highly luminescent Au(0)@Au(I)–
thiolate NCs. X in the Au(I)-X complexes can be any non-thiolate functional 
group in the reaction mixture. 
 
 
Figure 3.10 ESI mass spectra of (a) the reaction solution of as-synthesized 
luminescent Au NCs, and (b) the aqueous solution of pure GSH (3 mM) after 
heating at 70 °C for 24 h. The most abundant species in (a) are GS-SG (at m/z 
305 and 611 which are assigned to [GS-SG – 2H]2- and [GS-SG – H]- 
respectively) and the sulfonic acid derivative of GSH (at m/z 354 which is 
assigned to [M – H]-; see the molecular structure of M in the inset). The base 
peak in (b) corresponds to GSH (at m/z 306 which is assigned to [GSH – H]-). 
The above ESI-MS analyses confirmed the reducing role of both thiol (in GSH) 
and disulfides (in GS-SG) in our reaction system. 
 
Figure 3.11a shows that the size of the as-synthesized Au(0)@Au(I)–
thiolate NCs was below 2 nm. The Au NCs were light-yellow in solution and 
bright-yellow in the dry state under visible light (inset of Figure 3.11b, item 1). 
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They emitted intense orange luminescence in both solution and solid state under 
UV light (inset of Figure 3.11b, item 2). The NCs displayed excellent stability, 
including storage in water at room temperature (25 °C, Figure 3.12a) and 
elevated temperature (80 °C, Figure 3.12b), in solutions of high salt 
concentration (e.g., 1 M NaCl, Figure 3.12c), and in common buffer solutions 
(e.g., 40 mM of HEPES buffer (pH 7), Figure 3.12d). The luminescence 
intensity changes were less than 30% even after prolonged storage (7 to 24 
days). The unique structure of these luminescent Au NCs was first suggested by 
their UV–vis absorption spectrum (Figure 3.11b, solid blue line), which shows 
an onset at 500 nm and a shoulder peak at ~ 400 nm. Neither surface plasma 
resonance (SPR at ~ 520 nm is typical for spherical nanocrystals larger than 2 
nm)2 nor molecular-like absorption of conventional thiolate-protected Au NCs 
(peaks at > 500 nm for Au-thiolate NCs with more than 15 Au atoms)3, 24, 46, 47 
was detected. The QY of the luminescent Au NCs calibrated with fluorescein 
was ~ 15%, which is orders of magnitude higher than the QY of the reported 
Au-thiolate NCs (typically 0.001% to 0.1%).1 The photoemission spectrum 
(Figure 3.11b, solid red line) shows a main peak at 610 nm with a shoulder peak 
at 565 nm which are in correspondence with the two emission peaks in the 
spectrum of the aggregated complexes (Figure 3.3a, solid red line). Similar to 
the aggregated complexes (Figure 3.3a, dotted red lines), the luminescent Au 
NCs also showed a broad excitation band (Figure 3.11b, dotted red line) and a 
large Stokes shift (> 200 nm). The microsecond-scale lifetimes (1.99 µs (61%), 
0.536 µs (29%) and 0.144 µs (8.9%)) of the luminescent Au NCs (Table 3.1 and 
Figure 3.5c) were also similar to the lifetimes of the aggregated complexes 
(Figure 3.5a and 3.5b). The similarity between the NCs and aggregated 
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complexes in terms of luminescence lifetime and spectral features suggests that 
the emission from Au NCs was derived from the AIE of Au(I)–thiolate 
complexes on the NC surface. 
 
 
Figure 3.11 (a) TEM and STEM (inset) images of the luminescent Au NCs. 
(b) UV–vis absorption (solid blue line), photoemission (solid red line, λex = 365 
nm) and photoexcitation (dotted red line, λem = 610) spectra of the luminescent 
Au NCs. The insets are digital photos of the luminescent Au NCs in the solid 




Figure 3.12 Time-course UV–vis absorption (dashed lines) and 
photoemission (solid lines) spectra of the as-synthesized luminescent Au NCs 
in various experimental conditions: (a) in water at 25 °C, (b) in water at 80 °C, 
(c) in 1 M NaCl solution at 25 °C and (d) in a 40 mM HEPES buffer solution 




The high content of Au(I)–thiolate complexes in the luminescent Au NCs 
was confirmed by XPS and TGA analyses. The XPS spectra in Figure 3.13a 
show that the oxidation state of Au in the luminescent Au NCs (black line) was 
between that of Au(I)–thiolate complexes (red line) and large Au(0) 
nanocrystals (blue line). The Au 4f spectrum of the luminescent Au NCs was 
then deconvoluted into Au(I) and Au(0) components with binding energies of 
84.3 and 83.7 eV, respectively. The Au(I) content determined as such was found 
to constitute ~ 75% of all Au atoms in the luminescent Au NCs. The thiolate-
to-Au ratio in luminescent Au NCs was estimated by TGA. As shown in Figure 
3.13b, GSH contributed ~ 56% of the luminescent Au NCs by weight, which 
can be translated into a thiolate-to-Au ratio of 0.84:1. This value is significantly 
higher than that of conventional Au-thiolate NCs with more than 15 Au atoms 
(see the inset of Figure 3.13b for the thiolate-to-Au ratios of some known Au-
thiolate NCs).1, 3, 24, 48-50 It is however close to 1:1 thiolate-to-Au ratio reported 
for many oligomeric or polymeric Au(I)–thiolate complexes.34, 51, 52 The high 
Au(I) content and high thiolate-to-Au ratio are indications of a high content of 





Figure 3.13 (a) Au(4f) XPS spectra of Au(I)–thiolate complexes (red line, 
prepared by mixing GSH and HAuCl4 at room temperature), as-synthesized 
luminescent Au(0)@Au(I)–thiolate NCs (black line), and large Au(0) 
nanocrystals (blue line, > 3 nm, prepared by the NaBH4 reduction of HAuCl4 
without any protecting agent). (b) TGA spectrum of the as-synthesized 
Au(0)@Au(I)–thiolate NCs. The inset shows the thiolate-to-Au ratios of the 
Au(0)@Au(I)–thiolate NCs and three conventional Au-thiolate NCs (Au102SR44, 
Au38SR24, and Au25SR18). 
 
The size of the luminescent Au NCs was further characterized by PAGE 
analysis and ESI-MS. The native PAGE (30%) analysis of luminescent Au NCs 
revealed five closely spaced luminescent bands under the UV light (inset of 
Figure 3.14a), indicating that our luminescent Au NCs were a mixture of NCs 
with minor differences in size. The mobility of Band 1 was similar to that 
reported for the Au33-39SG22-24 NCs (see Figure 3.2 for the detailed analysis),
3 
and hence the luminescent NCs were relatively large in size (the size increases 
from Band 1 to Band 5). ESI-MS was then used to determine the molecular 
formula of the NCs in each band. ESI is a soft ionization technique that can be 
used to determine the NC formula by analyzing the intact NC mass.1, 53, 54 The 
NC bands were individually cut from 4 preparative gels, added with 5 mL of 
ultrapure water at 4 °C to allow the NCs in the gels to diffuse out. 12 h later, the 
gel lumps were removed using syringe filters (0.45-µm pore size) and the 
resulting samples were purified by ultrafiltration (3000 Da molecular-weight 
cut-off) and suspended in 500 µL of ultrapure water for ESI-MS measurement. 
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The ESI mass spectra of the bands (Figure 3.14b) show a series of multiply 
charged anions, which can be deconvoluted into the corresponding mass spectra 
of the uncharged Au NCs (Figure 3.14c). Due to the uncertainty in the 
fragmentation of the GSH ligand during the synthesis and the ESI-MS testing, 
we could not find the molecular formulas of the intact or fragmented Au NCs 
that perfectly match the obtained mass spectra. However, for the intense peaks 
(e.g., the most intense peak of Band 2), we could assign molecular formulas on 
the basis of their well-defined isotope distributions (data not shown). For the 
less intense peaks, we could estimate their formulas from their mass difference 
from the assigned peak of Band 2. Hence, major peaks (indicated by arrows in 
Figure 3.14c) of the Au NCs from Bands 1 – 5 were chosen to represent the 
sizes of the NCs in the corresponding bands, and they could be assigned as 
Au29SG27, Au30SG28, Au36SG32, Au39SG35 and Au43SG37, respectively. The ESI-
MS measurements confirmed 1) the relatively large size of our luminescent NCs 
(> 29 Au atoms) and 2) a uniquely high thiolate-to-Au ratio (~ 0.9:1) as 






Figure 3.14 (a) Photoemission spectra (λex = 365 nm) of luminescent Au NCs 
separated from Bands 1 − 5 in the native PAGE gel (30%). The inset shows the 
digital photo of the PAGE bands of Au NCs under UV light. All bands moved 
from the negative to the positive electrode (+), with Band 1 showing the highest 
mobility. (b) ESI mass spectra and (c) the corresponding deconvoluted mass 
spectra of Au NCs harvested from Bands 1 − 5 in the PAGE gel. The arrows in 
(c) indicate the peaks that have been assigned molecular formulas to represent 
the size of Au NCs in each band. 
 
The size effect of Au-thiolate NCs on emission wavelength was evaluated 
by analyzing the photoemission spectra (Figure 3.14a) of Au NCs of different 
sizes (harvested from the PAGE gel as Bands 1−5 in Figure 3.14a inset). 
Contrary to the prediction from the Jellium model where larger-sized NCs 
should emit longer wavelengths,55 the main emission peak of our luminescent 
Au NCs was blue-shifted from 620 to 605 nm with the increase in their size 
(from Bands 1 – 5). This observation is however consistent with the AIE 
properties of aggregated complexes shown in Figure 3.6d where denser 
aggregates emitted at shorter wavelengths (vide infra). Larger Au NCs with a 
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denser aggregation of complexes in their shell should therefore emit at shorter 
wavelengths if the AIE was the principal source of emission. The experimental 
size-emission wavelength relationship is therefore an indirect proof of the 
proposed Au(0)@Au(I)–thiolate NCs structure and the AIE properties of the 
shell as the origin of luminescence. 
The unique optical properties (absorption and luminescence; Figure 3.11b 
and Figure 3.14a) and compositions (Figure 3.13 and Figure 3.14b−c) of 
luminescent Au NCs suggest a different structure from the conventional Au-
thiolate NCs (e.g., Au102SR44, Au38SR24, and Au25SR18).
48-50 As illustrated in 
Figure 3.15, the Au(I)–thiolate complexes in the shell of our luminescent Au 
NCs (item ii) were oligomers and very unlike the short Au(I)–thiolate motifs 
(mono- or di-meric Au(I)–thiolate complexes) that populate the surface of 
conventional Au-thiolate NCs (item i).56 The presence of oligomeric Au(I)–
thiolate complexes in our NCs was suggested by separate and  independent 
measurements. As shown by our ESI-MS analysis (Figure 3.14b−c), the overall 
size of our luminescent Au NCs was relatively large (> 29 Au atoms) and the 
thiolate-to-Au ratio (~ 0.9:1) was much higher than that of conventional Au-
thiolate NCs with a similar number of Au atoms (XPS and TGA analyses in 
Figure 3.13). On the other hand, the metallic Au(0) core of our luminescent Au 
NCs could be smaller than that in the conventional Au-thiolate NCs with similar 
overall sizes. This was suggested by the large energy gap (~ 400 nm) in the UV–
vis spectrum (Figure 3.11b). Hence, the thiolate-to-Au ratio for the Au(I)–
thiolate complexes in the shell of our luminescent NCs should be close to 1:1, 
and oligomeric Au(I)–thiolate complexes are the most likely complex species 
there. However, it is important to note that the detailed structure of the 
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luminescent Au NCs can only be revealed by total structure determination based 
on the X-ray crystallographic analysis of single crystals of the Au NCs, which 
is difficult to perform at the moment. 
 
 
Figure 3.15 Schematic illustration of the structure of our luminescent Au 
NCs with AIE (item ii) and conventional Au-thiolate NCs (item i) with short 
Au(I)–thiolate motifs.  
 
Reaction temperature and GSH-to-Au ratio were identified as the most 
critical factors in the synthesis of highly luminescent Au NCs. The optimal 
reaction temperature was ~ 70 °C where sufficient Au(I)-X complexes could be 
reduced to Au(0) atoms while the Au(I)–thiolate complexes were left largely 
unaffected. The in-situ generated Au(0) atoms were sequestered by the Au(I)–
thiolate complexes and slowly induced the aggregation of the resultant Au(0)-
on-Au(I)–thiolate intermediates into Au(0)@Au(I)–thiolate NCs. Both the 
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generation of Au(0) atoms (from the reduction of Au(I)-X complexes) and the 
preservation of Au(I)–thiolate complexes were important to a successful 
synthesis. Control experiments carried out at lower reaction temperatures (e.g., 
25 °C) formed only large aggregates of insoluble Au(I)–thiolate complexes 
(Figure 3.16). The insufficient reduction of the Au(I)-X complexes at low 
temperature led to the formation of insoluble Au(I)–thiolate complex 
aggregates. Another control experiment using a strong reducing agent NaBH4 
produced only a reddish brown non-luminescent dispersion of Au NCs (Figure 
3.17). The strong reducing agent NaBH4 was able to decompose Au(I)–thiolate 
complexes reductively into Au NCs. The content of Au(I)–thiolate complexes 




Figure 3.16 Digital photos of the product synthesized by reacting HAuCl4 (2 
mM) and GSH (3 mM) at 25 °C for 24 h. The product was viewed under visible 
(item 1) and UV (item 2) light. Insoluble aggregates of Au(I)–thiolate 





Figure 3.17 UV–vis absorption spectrum of Au nanocrystals prepared by 
mixing HAuCl4 (20 mM, 0.5 mL) and GSH (100 mM, 0.15 mL) with ultrapure 
water (3.6 mL) at room temperature for 10 min, followed by the addition of 
NaBH4 (200 mM, 0.75 mL, 0 °C); and the mixture was allowed to react for 3 h 
at 25 °C. The inset shows the digital photos of the product under visible (item 
1) and UV (item 2) light. 
 
The GSH-to-Au ratio was another critical synthesis parameter. Control 
experiments were also carried out with GSH-to-Au ratios of 0.5:1, 1.5:1 and 
2:1. As shown in Figure 3.18, the optimized GSH-to-Au ratio of 1.5:1 was 
effective in producing luminescent Au NCs. A higher GSH-to-Au ratio (2:1) 
produced large Au(I)–thiolate complex aggregates while lower ratios (0.5:1) 
only formed large Au nanocrystals without any luminescence. The GSH-to-Au 
ratio of 1.5:1 provided a good balance between the amounts of Au(I)–thiolate 
complexes and Au(I)-X complexes so that the in-situ reduction of the latter 
generated the Au(0) atoms for the aggregation of the Au(I)–thiolate complexes 





Figure 3.18 Digital photos of the products synthesized by mixing HAuCl4 
(2 mM) and GSH with different GSH-to-Au ratios: (a) 0.5:1, (b) 1.5:1, and (c) 
2:1, at 70 °C for 24 h. The vials were viewed under visible (upper row) and 
UV (lower row) light. 
 
3.3.3 General utility of the synthesis method 
The synthesis method presented above is scalable (e.g., to 100 mL, Figure 3.19). 
It is also suitable for the preparation of luminescent Au NCs protected by other 
thiolate ligands, as demonstrated by the following examples. In one experiment, 
GSH was replaced by other custom-designed tri-peptides with the general 
formula of Am-Cys-Am where Am is an amino acid residue with a desired 
functional group. The cysteine residue in the middle of the tri-peptide is crucial 
to the synthesis as the provider of the thiolate ligand to generate Au(I)–thiolate 
complexes. We tested three types of amino acid residues for the Am position: 
(a) glutamic acid with a carboxyl side group, (b) serine with a hydroxyl side 
group, and (c) histidine with an imidazole side group. All of the custom-
designed tri-peptides formed luminescent Au NCs with an emission peak at ~ 
610 nm, as shown in Figure 3.20a–c. Hence by using peptides with a customized 
length and sequence, highly luminescent Au NCs with the desired surface 





Figure 3.19 Digital photos of the as-synthesized Au(0)@Au(I)–thiolate NCs 




Figure 3.20 UV–vis absorption (solid blue lines), photoexcitation (dotted red 
lines) and photoemission (solid red lines) spectra of luminescent Au NCs 
synthesized by custom-designed tri-peptides: (a) Glu-Cys-Glu, (b) Ser-Cys-Ser, 
and (c) His-Cys-His. The excitation spectra were measured at λem = 640, 620 
and 625 for (a) to (c), respectively, and the emission spectra were measured at 
λex = 365 nm for (a) to (c). The insets show the digital photos of the 






In summary, an interesting aggregation-induced emission (AIE) property was 
discovered in the Au(I)–thiolate complex system. Non-luminescent oligomeric 
Au(I)–thiolate complexes were found to emit strong luminescence after dense 
aggregation by either a solvent-induced or cation-induced method. The intensity 
and color of the luminescence were largely determined by the degree of 
aggregation. On the basis of this discovery, a simple one-pot synthesis for 
highly luminescent Au-thiolate NCs was developed using a common thiolate 
ligand, GSH as the reducing cum protecting agent. The Au-thiolate NCs 
fabricated as such had a Au(0)@Au(I)–thiolate core-shell structure formed by 
the controlled aggregation of Au(I)–thiolate complexes on in-situ generated 
Au(0) cores. High QY (~ 15%), large Stokes shift (> 200 nm) and the 
combination of ultrafine size, low toxicity and good biocompatibility, make 
these luminescent Au-thiolate NCs highly effective as   luminescence probes in 
various bio-settings. This facile synthesis method is scalable, and can be applied 
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CHAPTER 4    
On the Photoluminescence of Aun(SR)m Nanoclusters: 
Origin, Tunability, and Quantum Yield 
Thiolate-protected gold nanoclusters (or Au–thiolate NCs for short) are 
ultrasmall Au nanoparticles (NPs) with core sizes smaller than 2 nm.1 They are 
commonly denoted using molecular formula as Aun(SR)m, where –SR is the 
thiolate ligand. Thiolated Au NCs show highly size-sensitive molecule-like 
properties, such as quantized charging,2, 3 magnetism,4 optical chirality,5-8 
molecule-like absorption peaks in the UV–Vis–Near-IR region,9 and strong 
photoluminescence (PL),10-12 The PL of thiolated Au NCs in combination with 
their ultrasmall size, good chemical stability, high biocompatibility, and low 
toxicity has enabled the NCs as an emerging class of optical probes in 
developing applications such as sensing, labeling, and imaging in biomedical 
settings.11 Great interest is to be attributed to the fundamental issues with the 
PL properties of the thiolated Au NCs, such as the origin of luminescence, size 
and structure effects on the luminescence, and critical factors that affect the 
Quantum Yields (QYs) and emission tunability.1, 10, 12 The understanding of 
these issues is essential for improving the design and synthesis of thiolated Au 
NCs with strong and tunable emission and developing new applications. 
The origin of the luminescence of thiolated Au NCs has been widely 
attributed to the fluorescence from the discrete electronic transitions of their 
metallic Au cores. This was supported by the studies based on the highly 
fluorescent Au NCs protected by dendrimers (e.g., poly(amidoamine) or 
PAMAM for short).13 The emission energies of the dendrimer-protected Au 
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NCs was highly size-dependent and could be fitted with a simple jellium model: 
Eemission = EFermi (number of Au atoms)
–1/3. Another possible origin of 
luminescence is the surface of the thiolated Au NCs where the Au–S interface 
locates.14-16 The thiolate ligand is bound to Au core via the strong covalent-like 
Au–S bond and could influence the luminescence of the thiolated Au NCs 
through ligand-to-metal charge transfer (LMCT).17 In addition, as revealed by 
the structures of thiolated Au NCs (e.g., Au102(SR)44 and [Au25(SR)18]
–), the 
surface of a NCs contains a layer of Au(I)–thiolate complex motifs, and certain 
Au(I) complex species are known to be luminescent.18 Thus, understanding the 
PL of Au(I)–thiolate complexes could be the key to elucidating the PL 
properties of thiolated Au NCs. We recently discovered that oligomeric Au(I)–
thiolate complexes could emit strong luminescence by the mechanism of 
aggregation-induced emission (AIE).19 On the basis of this finding, a facile 
synthesis of highly luminescent (QY ~ 15%) thiolated Au NCs with orange 
emission (~610 nm) originated from the AIE of the complex motifs on their 
surface was developed by utilizing a mild reducing environment to preserve the 
oligomeric complexes and condense them onto the in situ generated Au(0) 
cores. The resultant orange-emitting thiolated Au NCs are unique because they 
have high content of relatively long Au(I)–thiolate complex motifs and few 
Au(0) in their cores as compared with similar-sized common thiolated Au NCs 
(e.g., Au15(SR)13, [Au25(SR)18]
– and Au38(SR)24) synthesized using “modified” 
Brust method.9 Contrary to the jellium model, the emissions of these NCs were 
blue-shifted (from 620 to 605 nm) as the sizes of these NCs increased (from 




Despite intensive research on the luminescent Au NCs, fundamental 
understanding of the origin of luminescence and the effects of size and structure 
on the PL properties (e.g., QYs and emission color) of common thiolated NCs 
synthesized using “modified” Brust method is still unclear. For example, no 
obvious trend in the emission wavelength or QYs has been observed for 
common thiolated NCs with increasing sizes.9 Inspired by the role of oligomeric 
Au(I)–thiolate complexes in the PL of thiolated Au NCs with AIE, we 
hypothesize that Au(I)–thiolate complex motifs could contribute significantly 
to or even dominate the generation of luminescence in common thiolated Au 
NCs. We further hypothesize that studying the evolution of size, structure, and 
optical properties from the complex precursors to NCs in the modified Brust 
Syntheses could shed light on the role of the Au(I)–thiolate complex motifs in 
the PL of common thiolated Au NCs and the effects of size and structure of 
thiolated Au NCs on their PL. 
Herein, by controlling the extent of the reductive decomposition of Au(I)–
thiolate complexes, intermediates of the synthesis can be obtained, and the 
growth of the NCs and the evolution of their optical properties are studied. The 
most important finding is that the major PL of both Au(I)–thiolate and thiolated 
Au NCs are in near-IR regime, and source of the emission of thiolated Au NCs 
are the Au(I)–thiolate complex motifs on their surfaces. The presence of a metal 
core in the thiolated Au NCs can greatly enhance the PL of the Au(I)–thiolate 
complexes by restricting intramolecular motion of the complexes, but the metal 
cores does not affect the emission energy, which is likely controlled by the 
length of the complex motifs. In addition, the origin of excitation for the 
thiolated Au NCs include at least LMCT and energy transfer from excited core 
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states to the surface states. Such understanding allows us to design new 
synthetic approach to tune the near-IR PL of the NCs, and apply NCs 
synthesized from “modified” Brust method in bioimaging. 
4.1 Experimental section 
Chemicals. All chemicals were commercially available and used without 
further purification. Gold(III) chloride trihydrate (HAuCl4·3H2O), L-
glutathione in the reduced form (GSH), sodium borohydride (NaBH4), cadmium 
chloride (CdCl2), and glycerol were obtained from Sigma-Aldrich. 10X 
Phosphate buffered saline (PBS) was purchased from Bio-Rad (Cat. No. 161-
0780). Ethanol (≥99.8%) was supplied by Fisher Scientific. Ultrapure water 
(Milli-Q) with a resistivity of 18.2 MΩ·cm was used as the general solvent 
throughout the study. 
Syntheses of mixtures of Au:SG species with different extents of 
reduction. The synthesis of Au(I)–SG complex precursors were based on 
previously reported method. In a typical synthesis, 10X PBS (0.5 mL) was 
added to 2.35–3.60 mL water (the volume of water depended on the volume of 
NaBH4 needed). After that, aqueous solutions of GSH (15 µmol, 0.15 mL) and 
HAuCl4 (5 µmol, 0.25 mL) were added consecutively to the PBS solution under 
vigorous stirring. The reaction was allowed to proceed for 30 min. Aqueous 
solutions of NaBH4 (NaBH4-to-Au ratio is varied from 0.05:1 to 5:1) was then 
added to the corresponding precursor solutions in a dropwise manner to ensure 
smooth and sequential growth of the NCs. The reaction mixture was then 
incubated at room temperature with vigorous stirring for 30 min before stored 
at 4 °C. The resultant mixtures of Au:SG species are listed in Figure 4.1b. 
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Material Characterization. UV-vis absorption and photoluminescence 
(PL) spectra were recorded on a Shimadzu UV-1800 photospectrometer and a 
Horiba Jobin Yvon Fluorolog-3 spectrofluorometer. Electrospray ionization 
mass spectrometry (ESI-MS) was carried out on a Bruker MicroTOF-Q ESI 
time-of-flight system operating in the negative ion mode (sample injection rate 
120 µL·min-1; capillary voltage ~4 kV; nebulizer 1.5 bar; dry gas 4 L·min-1 at 
160 °C; and m/z 1000–6000). Native polyacrylamide gel-electrophoresis 
(PAGE) experiments were carried out using a vertical electrophoresis cell 
(PROTEAN II xi Cell, Bio-Rad) that employs gels with a size of 10 × 160 × 
200 mm. The resolving and stacking gel were prepared by 30 and 4 wt% of 
acrylamide monomers [acrylamide/bis-(acrylamide) = 37.5:1), respectively. 




4.2 Results and Discussion 
Thiolated Au NCs are commonly synthesized through the well-developed 
“modified” Brust syntheses, which generally comprise two major reaction steps: 
(I) the reduction of Au(III) to Au(I)–thiolate complexes by an excess of thiol 
(e.g., thiol-to-Au ratio ≥ 3:1) and (II) the reduction of Au(I)–thiolate complexes 
to thiolated Au NCs by a strong reductant such as NaBH4 in excess (e.g., 
NaBH4-to-Au ratio ≥ 2:1). Obtaining and analyzing the intermediate states of 
the reaction solution is essential for investigating the synthetic process. As the 
reducing power of the reductant drives the conversion from Au(I)–thiolate 
complexes to thiolated Au NCs (Step II), the intermediate states of the reaction 
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solution could be obtained by controlling the amount of the reductant used for 
the synthesis. Figure 4.1a illustrate the typical synthetic processes for reaction 
solutions with different extents of reduction. The biocompatible tripeptide L-
glutathione (GSH or H-SG) was chosen as the model thiol in this study. In Step 
I, Au(III) was reduced to Au(I)–thiolate complexes by sufficient thiol (thiol-to-
Au ratio = 3:1) at 25 °C in 30 min (Step I). Phosphate buffered saline (PBS, 1X) 
was used to maintain the pH of the reaction solution at around pH 7. In Step II, 
Au(I)–thiolate complex precursors were reduced by different amount of NaBH4 
to obtain reaction solutions with different extents of reduction. 
 
 
Figure 4.1 (a) Schematic illustration of synthetic process, where –SR 
denotes the thiolate ligand. (b) Table showing the labels of the reaction solutions 
and the corresponding NaBH4-to-Au ratios. 
 
Seven reaction solutions (M0 to M6) were prepared using different amount 
of NaBH4 (NaBH4-to-Au ratio from 0 to 5:1) while keeping Au amount constant 
(Figure 4.1b). The colors of the solutions under room light change from 
colorless to dark brown (Figure 4.2a, top row) with increasing NaBH4-to-Au 
ratios (or extents of reduction). In addition, red emission can be observed from 
reaction solutions with intermediate extents of reduction (M1 to M5) under UV 
irradiation (Figure 4.2a, bottom row). As M0 to M6 were expected to be 
mixtures of different Au:SG species, native polyacrylamide gel electrophoresis 
 

















(PAGE, 30%) were used to analyze the Au:SG species in these solutions. The 
resultant gel was viewed under both room light (Figure 4.2b, top panel) and UV 
light (Figure 4.2b, bottom panel). The mixtures were separated into several 
Au:SG species that are labeled from Band 1 to 7. Due to the light color of Band 
1 and 2, they are not clearly visible under room light, but they are distinct dark 
bands under UV light. Band 5 and 6 have very similar mobility. However, Band 
5 Au:SG species shows red emission under UV light and appear mainly in 
reaction solutions with lower extent of reduction (e.g., M1 to M4), whereas 
Band 6 Au:SG species does not show visible luminescence under UV light and 
appears pure in M6 (NaBH4-to-Au ratio m= 5:1). Negative-ion ESI-MS was 
carried out to identify the molecular formulas of the Au:SG species of each 
band. The mass spectrum of each band mainly comprises anions of a single 
Au:SG species with different charges (Figure 4.2f) except that Band 5 contains 
a significant amount of Au:SG species of neighboring bands (Band 4 and 6). 
The molecular formulas of the thiolated Au NCs in these bands were assigned 
by comparing the mass spectra of the bands (Figure 4.2g, black lines) with 
simulated isotope distributions (Figure 4.2g, red lines), and the molecular 






Figure 4.2 (a) Digital photos of the reaction solutions with different extents 
of reduction under room light (top row) and UV light (bottom row). (b) The gel 
from the native PAGE of the reaction solutions viewed under room light (top) 
and UV light (bottom). (c) ESI-MS spectra of the bands isolated from the PAGE 
gels. (d) The comparison of the isotope distributions of the isolated Au:SG 
species (black lines) and the corresponding molecular formulas (red lines). (e) 
UV–vis absorption and (f) emission (PL) spectra of the reaction mixtures. The 
excitation wavelength (λex) for PL spectra was 365 nm. (g) Normalized 
photoluminescence excitation (PLE) spectra of unreduced Au(I)–thiolate 
complexes (M0) and selected NaBH4-reduced reaction solutions (M4, M3, and 
M6) measured using different emission wavelengths. 
  
 






















 M0,   em = 770 nm
 M0,   em = 920 nm
 M0,   em = 1050 nm
 M4,   em = 770 nm
 M3,   em = 920 nm
 M6,   em = 1050 nm
 
 




















































Table 4.1 Molecular formulas and numbers of free valence electrons (n*) 
of the NCs in the PAGE bands. 
Band Molecular formula n* 
1 Au10(SG)10 0 e– 
2 Au15(SG)13 2 e– 
3 Au18(SG)14 4 e– 
4 Au22(SG)16 6 e– 
5 Au22(SG)18 4 e– 
6 [Au25(SG)18]– 8 e– 
7 [Au29(SG)20]– 10 e– 
 
The distribution of Au:SG species in the reaction solutions reveals a bottom-
up growth mechanism (Figure 4.2e and Table 4.1). With low extent of reduction 
(e.g., M1), NCs with lower number of free valence electrons or n* (e.g., 
Au15(SG)13 and Au18(SG)14) form first. As the extent of reduction increase (M2 
to M6), NCs with higher n* (e.g., [Au25(SG)18]– and [Au29(SG)20]–) grow and 
become dominant while Au(I)–thiolate complexes and NCs with lower n* are 
consumed. The bottom-up growth of the thiolated Au NCs is supported by the 
absorption spectra of the reaction solutions (Figure 4.2e), which show increases 
in absorption in visible to near-IR range (400–1000 nm) as the extents of 
reduction increases (Figure 4.2e). The fine absorption features (Figure 4.2e, 
inset) are also consistent with the PAGE results. For examples, the absorption 
shoulder at ~565 nm, which is a feature of both Au18(SG)14 and Au22(SG)16, 
increases from M1 to M3 then decreases until hardly distinguishable in M6, 
whereas the shoulder at ~670 nm, which is a absorption feature of [Au25(SG)18]
–
, becomes prominent in M5 and M6.9, 20 
Only Au22(SG)16 and Au22(SG)18 seemed to contribute to the red 
luminescence of M1 to M5 as shown in the PAGE gel (Figure 4.2b, bottom), 
but the emission (PL) spectra (Figure 4.2f) revealed that the unreduced reaction 
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solution (M0) and NaBH4-reduced reaction solutions (M1 to M6) all shows 
emission in the near-infrared (near-IR) regime. The PL spectrum of M0 shows 
weak emission ranging from 650 to 1300 nm (centered at ~920 nm) and consists 
of multiple peaks. The photoluminescence excitation (PLE) spectra of M0 
measured with λem = 770, 920, and 1050 nm (Figure 4.2g, black, purple, and 
magenta lines, respectively) show that the main excitation peaks were all at 
~350 nm (Figure 4.2g). The absorption shoulder peaks at 330 and 375 nm in 
UV–vis spectrum of M0 (Figure 4.2e) suggests that M0 are mostly oligomeric 
Au(I)–thiolate complexes no larger than Au10–12(SG)10–12.19 Such a low-energy 
NEAR-IR emission and a large Stokes shift (~2.2 eV) have not been reported 
for oligomeric Au(I)–thiolate complexes, but similar PL features were observed 
for a series of Au(I)–selenido complexes (e.g., [Au10Se4(dpppe)4]2+).21  The 
origin of the PL of the oligomeric Au(I)–thiolate complexes could be attributed 
to the excitation via a ligand-to-metal charge transfer (LMCT) transition from 
the sulfur of the thiolate ligand to the gold as reported for many other Au(I)–
chalcogenido and –chalcogenolate complexes.18, 22 The large Stokes shift 
suggests that the excited state structures of the oligomeric Au(I)–thiolate 
complexes originated from the LMCT are highly distorted from those of the 
ground states and that the relaxation pathway may involve an intersystem 
crossing to triplet states before radiative decay as the presence of the heavy Au 
center can facilitate the access to triplet excited states by enhancing the spin-
orbit coupling of the system.18, 21-24 
The PL spectra of M1 to M6 also shows multiple peaks and variation in the 
intensities of the peaks resulted in an apparent bathochromic shift from ~920 to 
~1050 nm from M1 to M6. Remarkably, the emission energies of the peaks in 
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the PL spectra of M1 to M6 matches those of M0 (Figure 4.2f). The matching 
emission energies suggests that the near-IR emission from the thiolated Au NCs 
in M1 to M6 are likely from their Au(I)–thiolate complex motifs that are closely 
related the Au(I)–thiolate complexes in M0. In addition, it can be inferred that 
the metallic Au cores of the NCs does not have a significant impact on the 
emission energies of the NCs, as the emission energies of the peaks did not 
change among M0 to M6. Thus, we hypothesize that the near-IR emission 
energies of peaks of the NCs are controlled by the sizes (or structures) of the 
Au(I)–thiolate complex motifs on the NCs only, and the distribution or the 
pattern of the emission peaks depends on the relative amount of the different 
motifs. As the core size or the number of free electrons increase, the complex 
motifs on the NCs are generally decrease in size. For example, Au15(SR)13 is 
simulated to have two timer motifs and one cyclic pentamer motif interlocked,25 
whereas [Au25(SR)18]− and Au144(SR)60 has only dimer and monomer motifs, 
respectively.20, 26, 27 Thus, it can be inferred that thiolated Au NCs with shorter 
complex motifs emits at longer wavelengths. 
The main peaks in the PLE spectra (Figure 4.2g) of the thiolated Au NCs 
(M4, M3, and M6) measured at emission wavelengths 770, 920, and 1050 nm 
were at 350, 360, and 375 nm, respectively, which are also very similar to the 
excitation peak of M0 (~350 nm) and can be attributed to the excitation via 
LMCT. However, in contrast to the relatively narrow excitation peak of M0, the 
excitation spectra of the thiolated Au NCs show long tails from 400 to 850 nm 
with shoulder peaks matching those of the absorption spectra of the NCs (Figure 
4.2e). For example, the PLE spectrum of M6 measured with λem = 1050 nm 
(Figure 4.2g, blue line) shows a shoulder peak at 670 nm, which corresponds to 
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the absorption peak of [Au25(SG)18]
− arising almost entirely from the electronic 
transition of the Au13 core of the NC.
20 As the Au(I)–thiolate complex motifs 
are the source of the near-IR emission, an energy transfer from the metallic Au 
core to the surface motifs is expected during the relaxation of the excited 
states.28 Thus, the near-IR PL of thiolated Au NCs may be originated from at 
least two excitation pathways: excitation via LMCT and metal core excitation 
followed by energy transfer to the surface. 
Though the presence of metallic Au cores does not seems to affect the 
emission energies of the near-IR PL of thiolated Au NCs, it can significant 
enhance the QYs of the Au(I)–thiolate complexes. As shown in Table S1, the 
QYs of the NaBH4-reduced reaction solutions (M1 to M6) are about 20 to 70 
times as high as that of the unreduced oligomeric Au(I)–thiolate complexes 
(M0). The remarkable difference in QYs between the thiolated Au NCs and the 
oligomeric Au(I)–thiolate complexes suggests that significant non-radiative 
decay of the excited states occurs for the free complexes in solution, which may 
be effectively prevented by the presence of metallic Au core. Considering the 
flexible structures of the oligomeric Au(I)–thiolate complexes in solution phase, 
the non-radiative decay could be accounted for by the severe intramolecular 
rotation and vibrations. The metallic Au core of the thiolated Au NCs effectively 
serves as a substrate that can fix the Au(I)–thiolate complexes on its surface 
through bonding with the gold and sulfur atoms of the complexes, thereby 
significantly restrict the intramolecular rotation and vibrations and reduce non-
radiative decay. Similar restriction of intramolecular motion (RIM) has been 
reported as the main factor that can enhance the PL of luminophore systems, 
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including organic, organometallic, and polymeric luminogens, in a remarkable 




In summary, by controlling the extent of reduction of Au(I)–thiolate 
complex precursors, we were able to study the composition and optical 
properties of the intermediate reaction solutions. The PAGE and ESI-MS results 
clearly suggest a bottom-up growth process where thiolated Au NCs with 
smaller number of free valence electrons (n*) form first and then grow into NCs 
with larger n*. We discovered that the major part of emission of both Au(I)–
thiolate complexes and thiolated Au NCs is in near-IR regime. By comparing 
the PL spectra of thiolated Au NCs with Au(I)–thiolate complexes, we 
concluded that the emission source of the NCs the Au(I)–thiolate complex 
motifs on the NC surface, and the emission energies depends on the length of 
the motifs. The PLE spectra of the thiolated Au NCs suggests that their 
excitation origin include at least LMCT and the energy transfer from excited 
cores to the surface motifs. The metallic Au cores do not affect the emission 
energies of the NCs, but it can significant enhance the PL intensity of the 
complex motifs by restricting their intramolecular motion. Such understanding 
could lead to the development of new synthetic approaches for highly 
luminescent thiolated Au NCs with tunable near-IR emission, and application 
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CHAPTER 5    
Toward Understanding the Growth Mechanism: Tracing 
All Stable Intermediate Species from Reduction of Au(I)–
Thiolate Complexes to Evolution of Au25 Nanoclusters 
5.1 Introduction 
Thiolate-protected gold nanoclusters (or thiolated Au NCs)1-5 have attracted 
tremendous research interests in the past two decades because of their 
distinctive molecular-like properties such as quantized charging,6, 7 intrinsic 
chirality,8-10 and photoluminescence.11-14 Despite the great progress in synthesis 
and characterization, the mechanistic studies of NC formation still significantly 
lag behind.15 The most common synthesis of thiolated Au NCs starts with the 
formation of polymeric Au(I)–thiolate complexes from the reaction between 
Au(III) salts and thiols, followed by reduction with excess borohydride. The 
resultant NCs can be converted into monodisperse or atomically precise NCs 
through a thermodynamic size selection (or size-focusing) process of thiol 
etching.16-18 However, how the NCs are formed from the reduction of Au(I)–
thiolate complexes, how they grow into a mixture of NCs, and how the magic 
sizes evolve out of the mixture are still experimentally unknown. 
By employing a CO-directed, well-controlled reduction that transforms 
well-defined Au(I)–thiolate complexes into atomically precise thiolated Au25 
NCs, here we identify all stable intermediate species using electrospray 
ionization mass spectrometry (ESI-MS)19, 20 and analyze their evolution 
throughout the course of synthesis. This time-tracing analysis reveals a bottom-
up growth mechanism and novel reactive Au(I) complex precursors such as 
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[Au3(SR)3Cl]– that are susceptible to CO reduction. The identified intermediates 





Chemicals. All of the chemicals were commercially available and used without 
further purification. Gold(III) chloride trihydrate (HAuCl4·3H2O), 3-
mercaptobenzoic acid (m-MBA), acetic acid, N,N-dimethylformamide (DMF) 
were purchased from Sigma-Aldrich. Sodium hydroxide, sodium chloride, and 
ethanol were purchased from Merck. Carbon monoxide was provided by 
SOXAL. Ultrapure water (Milli-Q) with a resistivity of 18.2 MΩ·cm was used 
as the solvent for the synthesis. 
Characterization of the reaction solutions. Intermediate reaction 
solutions were withdrawn using a needle syringe through a rubber cap on the 
round bottom flask. The samples were diluted with water before measuring its 
UV–vis absorption spectra. The reaction solutions were processed in the 
following way for ESI-MS measurements. Each reaction solution (200 µL) was 
first mixed with an aqueous solution of sodium chloride (2.5 M, 20 µL), 
followed by mixing with ethanol (1.3 mL). The mixture was centrifuged at 
10000 rpm for 6 min at 25 °C. The resulting pellet was washed by DMF (1 mL) 
and centrifuged at 10000 rpm for 3 min at 25 °C. The pellet was then dissolved 
in 450 µL DMF with 50 µL acetic acid before ESI-MS measurement. 
UV–vis absorption spectroscopy was measured with a Shimadzu UV-1800 
photospectrometer. Electrospray ionization mass spectrometry (ESI-MS) was 
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done on a Bruker MicroTOF-Q ESI time-of-flight system operating in the 
negative ion mode (sample injection rate 8 μL·min−1, capillary voltage 4 kV, 
nebulizer 1.5 bar, dry gas 4 L·min−1 at 120 °C, and m/z 100–5000) was used for 
electrospray ionization mass spectrometry (ESI-MS). The ESI-MS spectra 
presented in this study were obtained by accumulating for 20 min. 
Fourier transform infrared spectroscopy (FTIR) was conducted on a Bio-
Rad FTS 3500 ARX instrument. The spectra for the freeze-dried samples of the 
precursor solution, the reaction solution at pH 7 (at 20 min after bubbling CO), 
and the reaction solution at pH 11.6 (at 20 min after bubbling CO) were recorded 
at a resolution of 1 cm−1. Samples were prepared in KBr pellets. 
Total inorganic carbon (TIC) analysis was conducted on a Shimadzu TOC-
V CSH analyzer to determine the concentration of inorganic carbon in the 
solution. The standard was prepared with anhydrous sodium bicarbonate and 
anhydrous sodium carbonate in ultrapure water. The reaction solution (4.5 mL) 




5.3 Results and discussion 
The facile one-pot CO-directed synthesis of thiolated Au25 NCs was based on a 
reported method.21, 22 We chose the mild gaseous reducing agent CO to ensure 
that the reduction kinetics is slow (relative to the reduction by borohydride) and 
can be readily stopped, so we could track the reaction intermediates. A simple 
thiol, 3-mercaptobenzoic acid (m-MBA), was used as the model thiolate ligand. 
In a typical synthesis, aqueous solutions of m-MBA (50 mM in 150 mM NaOH, 
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0.4 mL) and HAuCl4 (40 mM, 0.25 mL) were added into a 25-mL round bottom 
flask containing 9.5 mL ultrapure water under stirring (500 rpm). After 2 h, the 
color of the reaction solution turned light yellow, indicating that Au(III) was 
reduced to Au(I) complexes. The pH of the solution was then brought to 11.6, 
and CO was bubbled through for 2 min. Then, the flask was sealed airtight, and 
the reaction was allowed to proceed for 72 h. Figure 5.1a illustrates the designed 
synthetic process, which starts with the kinetically controlled reduction of 
soluble Au(I)–thiolate complexes and the initial growth of NCs to form a 
mixture of thiolated Au NCs with a relatively narrow size distribution (Stage I); 
a long (~3 days) thermodynamically controlled size-focusing process then 




Figure 5.1 (a) The designed CO-directed synthesis of the atomically precise 
thiolated Au25 NCs; (b) UV–vis absorption and (c and d) ESI-MS spectra of the 
product obtained from the synthesis. Inset of (b), photo of the product under 
room light. The red line in (d) is the simulated isotope distribution of [Au25(m-
MBA)18 – 2H+]3–. 
 
Before demonstrating the growth process, we first show that after Stage II 
highly pure [Au25(m-MBA)18]
– NCs were formed as the final product. The UV–
vis absorption spectrum of the raw product shows well-defined features at 430, 
480, and 690 nm (blue arrows in Figure 5.1b) and slight shoulder absorption 
peaks at ~575 and ~815 nm (red arrows in Figure 5.1b) which agrees well with 
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the reported spectra of anionic thiolated Au25 NCs.
23 The yield of [Au25(m-
MBA)18]
– was estimated to be >90% by comparing their molar absorptivity with 
Au25 NCs protected by glutathione (GSH).
20 The ESI-MS spectrum of the 
product NCs (Figure 5.1c) displays only two sets of peaks at around 2580 (triply 
charged ions) and 3870 (doubly charged ions) m/z in the range of 1000–5000 
m/z. Both sets of peaks are attributed to [Au25(m-MBA)18]
–, corroborating the 
high purity of the NCs and the high yield of the synthesis. The isotope 
distribution of the base peak (Figure 5.1d, black line) matches with the 
simulated isotope distribution of [Au25(m-MBA)18 – 2H+]3– (Figure 5.1d, red 
line), which confirms that the molecular formula of the final product is [Au25(m-
MBA)18]–. 
Now we show the reduction of Au(I)–thiolate complexes and the initial 
growth process of Au NCs. Both the UV–vis absorption (Figure 5.2a–c) and 
ESI-MS (Figure 5.2d and 2e) spectra of the reaction solution were measured at 
different time points starting from the moment immediately before the bubbling 
of CO (referred to as precursors) to 72 h after the bubbling of CO. The UV–vis 
absorption spectra of the reaction solution show a gradual increase in 
absorbance from 400 to 800 nm in the first 60 min (Figure 5.2a), indicating the 
formation and growth of thiolated Au NCs.20 Correspondingly, the color of the 
solution turned from light-yellow (color of the precursors) to yellow-brown to 
brown (insets of Figure 5.2a and b). From 60 min to 24 h, the UV–vis absorption 
spectra (Figure 5.2b) mainly show the growth of the characteristic peaks of 
[Au25(m-MBA)18]
– NCs, and these peaks become increasingly better defined 
from 24 to 72 h (Figure 5.2c). The color of the solution turned from brown to 




Figure 5.2 Time evolution of (a–c) UV–vis and (d and e) ESI-MS spectra 
of the reaction solution during the synthesis of [Au25(SR)18]– (where SR denotes 
m-MBA). Insets in (a–c), photos of the reaction solution at different time points. 
The black, blue, and red labels in (d and e) indicate that the ionic species are 
singly, doubly, and triply charged, respectively. The right panel in (e) are the 
molecular formulas and the classification of the labeled species according to the 
number of free valence electrons (n*). 
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ESI-MS spectra of the reaction solution (Figure 5.2d–e) were obtained with 
isotope resolution. Surprisingly, we were able to identify all the precursors and 
intermediates at different time points. The slow, mild, and readily stoppable CO 
reduction made this possible. In total, 29 species with a general molecular 
formula of [AuM(SR)NClP]
q (where SR denotes m-MBA) were identified. As 
shown in Figure 5.2e, right panel, these species can be classified into six groups 
according to the number of free valence electrons, n* = M – N – P – q, where 
M, N, P and q are the number of Au atoms, the number of thiolate ligands, the 
number of chloride ligands, and the net charge of the molecule, respectively.24 
All precursor species are Au(I) complexes (n* = 0), confirming that the 
relatively low thiol-to-Au ratio used in our synthesis (2:1 as compared with the 
commonly used 3:1 or higher) is sufficient in reducing Au(III) to Au(I).13, 25 The 
Au(I) complex precursors include the homoleptic Au(I)–thiolate complexes 
with the general formulas Aun(SR)n and [Aun(SR)n+1]
– and the heteroleptic 
Au(I) complexes that have both thiolate and chloride ligands [Aun(SR)n–pClp+1]
–
, where p = 0 or 1. The formation of [Aun(SR)n–pClp+1]
– is likely a result of the 
lack of free thiols due to the low thiol-to-Au ratio used in our synthesis because 
free thiols are able to replace the chloride ligands of Au(I)–chloride complexes 
in water or polar solvents.26, 27 The identified NCs all have even-numbered n* 
ranging from 2 to 10. It is of note that many of the identified NCs here were 
reported previously, for example by Negishi et al. via the separation of a mixture 
of GSH-protected Au NCs up to Au39 from NaBH4 reduction.
20 But the novelty 
of the present work is that we slowed down the reduction and traced the time 
evolution of the precursors and the intermediate NCs leading to highly pure 
[Au25(SR)18]
–, so we could better understand the formation and growth 
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mechanism. To track each intermediate, we plot the time evolution of its ESI-
MS peak intensity in Figure 5.3. At first sight, one can see two distinctive stages 
as suggested in Figure 5.1a. Stage I (the first ~40 min) was the kinetically 
controlled growth of the NCs, which converted most Au(I) complexes into a 
narrow distribution of intermediate NCs with n* ranging from 4 e– to 10 e–. 
Stage II (from ~40 min onwards) was the thermodynamically controlled, slow 







Figure 5.3 Normalized ESI-MS spectral intensity profiles of the complex 
and NC species throughout the synthesis. 
 
Stage I was initiated by CO reduction of Au(I) complex precursors: 
Aun(SR)n, [Aun(SR)n+1]
–, and [Aun(SR)n–pClp+1]
–.  Figure 5.4 shows their DFT-
optimized structures. Aun(SR)n (when n > 2) complexes are cyclic,
28 whereas 
the [Aun(SR)n–pClp+1]
– complexes are linear and can be considered as 
[Aun(SR)n+1]
– with one or both of the terminal thiolate ligands replaced by 
chloride. Figure 5.3 shows that Aun(SR)n and [Aun(SR)nCl]
– (n > 1) were 




species (n = 1 and 2) remained in the reaction solution throughout Stage II 
despite excess CO (~70 equivalents of Au), suggesting that these [Aun(SR)n+1]
– 





Figure 5.4 (a) DFT-optimized structures of the complex precursors as 
labeled in Figure 5.2 in the main text (R=CH3); (b) Proposed structure for 
Au11(SR)9: a Au4 tetrahedral core protected by a tetrametric and a trimeric staple 
motif. Au, orange; S, green; C, red; H, pink; Cl, light blue. 
 
Consumption of reactive Aun(SR)n and [Aun(SR)nCl]
– species leads to 
formation of AuM(SR)N (M > N) NCs. Figure 5.3 shows that 2 e
– NCs including 
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Au11(SR)9 and Au15(SR)13 were formed first. To our knowledge, this is the first 
time that Au11(SR)9 has been observed. How does the reduction of Aun(SR)n 
and [Aun(SR)nCl]
– species lead to Au11(SR)9 or Au15(SR)13? We propose a 
reduction-growth mechanism for the 2 e– NC formation, which consists of a 
reduction step and a subsequent growth step. We hypothesize that the reduction 
step happens via binding of CO to Au(I) of the reactive Au(I) complex 
precursors to form a linear monocarbonyl Au(I)–thiolate complex Aun(SR)nCO. 
The carbonyl group then reacts with the abundant hydroxide ions in the reaction 
solution (at pH 11.6) through a classic Hieber base reaction to form a 
metallacarboxylic acid [Aun(SR)nCOOH]
–.29 The decarboxylation of this 
intermediate drives the transfer of two electrons to the nearby two Au(I) atoms 
to reduce them to Au(0) and form a Au–Au bond. The decarboxylation 
mechanism is supported by a total inorganic carbon (TIC) analysis which 
indicates a stoichiometric amount of CO3
2– is present in the final reaction 
solution (data not shown). After losing two –SR groups, a charge-neutral 2 e– 
NC intermediate Aun(SR)n-2 is formed.
30 See Figure 5.5 for the details of the 
proposed CO reduction mechanism. As no signals of carbonyl or carboxyl Au(I) 
complexes were observed in ESI-MS (Figure 5.2d–e) or FTIR (Figure 5.6) 
analyses, the binding of CO to Au(I) is likely rate-determining. The Aun(SR)n-2 
from this step are small (n is from 2 to 10, limited by the precursor sizes) and 
expected to be very labile as their cores are quite open and susceptible to 
chemical attacks and further reactions.31 In the growth step, these small 
Aun(SR)n-2 NC intermediates will collide with another complex precursor and 
coalesce into a larger and more stable NC. This proposed two-step reduction-
growth formation of the 2 e– NC Au11(SR)9 can be written as in Figure 5.7: the 
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Au6(SR)6 precursor is reduced by CO to Au6(SR)4 which subsequently reacts 
with the Au5(SR)5 precursor to form Au11(SR)9. Using density functional theory 
with a continuum solvation model, we computed the overall reaction enthalpy 
for Au11(SR)9 formation in water according to Figure 5.7 and found it to be 
about -155 kcal/mol, indicating that the proposed reaction has a very favorable 
thermodynamic driving force. Likewise, Au15(SR)13 can be formed from the 
reduction-growth process that involves Au10(SR)10 and Au5(SR)5 and the 
computed reaction enthalpy is at -161 kcal/mol. 
 
 
Figure 5.5 Schematic illustration of the mechanism of the redox reaction 
between Au(I) complex precursors and CO that leads to the initial formation of 





Figure 5.6 FTIR spectra of the freeze-dried samples of the precursor 
solution (black line), the reaction solution at pH 7 at 20 min after bubbling CO 
(red line), and the reaction solution at pH 11 at 20 min after bubbling CO (blue 
line). The binding of CO to Au(I) was not observed in the FTIR spectra, 
irrespective of reaction pH. 
 
 
Figure 5.7 The proposed reduction-growth formation of Au11(SR)9. 
 
Figure 5.3 shows that the initial formation of 4, 6, 8 and 10 e– NCs also 
occurred in Stage I, slightly after 2 e– NCs. The temporal ordering of appearance 
suggests a sequential 2 e– reduction-growth process: 2 e– → 4 e– → 6 e– → 8 e– 
→ 10 e– (Figure 5.8). For example, the 4 e– Au18(SR)14 can be formed from CO 
reduction of Au3(SR)3 to Au3(SR)1 followed by its reaction with 2 e
– 
Au15(SR)13. In other words, Figure 5.3 suggests a bottom-up formation process 
via reduction-growth from the reactive Au(I) precursors to thiolated Au NCs 
with sequentially larger and even n*. The clear end of Stage I (or the relatively 
fast bottom-up growth of NCs) is a result of the depletion of reactive Au(I)–
thiolate complex precursors that fueled the growth of NCs. 
 





Figure 5.8 Schematic illustration of the bottom-up growth of thiolated Au 
NCs.  
 
Stage II is characterized by the relatively slow size-focusing process that 
eventually produced the highly pure [Au25(SR)18]
–. Conventional size-focusing 
method usually involves etching a mixture of larger NCs into smaller, more 
stable NCs and Au(I)–thiolate complexes by using excess thiols at elevated 
temperatures.32-34 The size-focusing process here is different in that it involves 
mainly conversion of smaller NCs to larger ones. ESI-MS spectra suggest that 
there are at least three modes of NC inter-conversion and growth in Stage II: 
isoelectronic addition, disproportionation, and comproportionation reactions. 
For example, the ESI-MS spectra (Figures 2d–e and 3) and the residual UV–vis 
absorption spectra (Figure 5.9) indicate the growth of [Au23(SR)16]
– into 
[Au25(SR)18]
– from 24 to 72 h. The structures of [Au23(SR)16]
– and [Au25(SR)18]
– 
are highly symmetrical and closely related,35-37 and differ in their molecular 
formulas by a Au2(SR)2. While Au2(SR)2 or [Au2(SR)2Cl]
– was in negligible 
amount, [Au(SR)Cl]– was abundant in the reaction solution in the period of 24–
72 h (Figure 5.2d). Thus, [Au23(SR)16]
– may slowly grow into [Au25(SR)18]
– by 
isoelectronic addition of two units of –Au(SR)– as in Reaction 1, Figure 5.10. 





– is indeed thermodynamically 
favorable, though this driving force is much smaller than those of the reduction-
growth reactions in Stage I, consistent with the slow pace of Stage II 
conversions. Formation of 4 e– [Au15(SR)12]
– well after 6 e–, 8 e–, and 10 e– NCs 
in Stage II (Figure 5.3) suggests a disproportionation reaction, for example, 
between two [Au20(SR)15]
– as shown by Reaction 2, Figure 5.10.38 Consumption 
of [Au29(SR)20]
– (10 e–) indicates a reaction with another NC such as 
[Au21(SR)16]
– to produce two [Au25(SR)18]
– via a comproportionantion reaction 
(Reaction 3, Figure 5.10). Besides these three modes of reactions, the reduction 
by CO still occurs to increase n* of some intermediate NCs, but the reduction 
rate is much slower than that of Stage I due to the lack of reactive complexes or 
complex motifs on the NC surface.39, 40 On the basis of the observed time 
evolution of the NC species (Figures 2 and 3) and the above analyses of Stages 
I and II, we can propose plausible chemical equations of the formation and 
consumption of all the observed NCs during the synthesis (data not shown), 





Figure 5.9 The residual spectra obtained by arithmetically subtract the UV–
vis absorption spectrum of the reaction solution at 72 h from that of the reaction 
solution at 24 h (blue line) and vice versa (red line). The blue arrow indicates 
the characteristic absorption peak (at ~590 nm) of [Au23(SR)16]
−;37 the red 
arrows indicate the characteristic peaks (at 430, 480, 690, 575 and 815 nm) of 
[Au25(SR)18]
−.35, 41 The broad peak at ~590 nm corresponding to [Au23(SR)16]
− 
diminished while the characteristic peaks of [Au25(SR)18]
− increased from 24 to 





Figure 5.10 Isoelectronic addition, disproportionation and 
comproportionation reactions occurred during the size-focusing process (Stage 




We have monitored the entire transformation from Au(I) complex precursors to 
the magic [Au25(SR)18]
– using UV–vis spectroscopy and ESI-MS, enabled by 



















the mild CO reduction. Au(I)–thiolate complex precursors (including chloride-
containing ones) and stable NC intermediates have been clearly identified. On 
the basis of the time evolution of those species, we were able to propose a 
reduction-growth mechanism of the kinetically controlled NC formation in the 
fast Stage I and inter-cluster conversion pathways in the subsequent, 
thermodynamically controlled size-focusing to [Au25(SR)18]
– (Stage II). The 
present results represent an important step forward toward understating the 
growth mechanism of thiolated Au NCs and call for further time-resolved 
studies of precursor reduction, NC growth, and NC inter-conversion, in an effort 
to shed light on synthetic processes and to facilitate the development of 
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CHAPTER 6    
Higher Thiol-to-Au Ratio for synthesizing Larger Thiolated 
Nanoparticles: Dominance of Monomeric Au(I)–thiolate 
Complex Precursor Favors the Formation of Monodisperse 
~2 nm Nanocrystals 
6.1 Introduction 
In the past two decades, Au NPs protected by thiolate ligands have attracted 
tremendous interests due their high chemical stability as a result of the strong 
Au–S bond. The core size of the thiolate-protected gold nanoparticles (or 
thiolated Au NPs) is a critical factor that determines the physicochemical 
properties of the NPs. Thiolated Au NPs can be categorized into two groups 
according to their core sizes: nanocrystals (>2 nm) and nanomolecules (<2 nm), 
which have distinct size-dependent physicochemical properties.1 For example, 
thiolated Au nanocrystals show fascinating surface plasmon resonance (SPR), 
which shifts bathochromically as the size the nanocrystals increases.2-5 
Thiolated Au nanomolecules (or Au nanoclusters (Au NCs)) show molecular 
absorption features in the UV–vis spectra instead of SPR, and their absorption 
edge generally shifts bathochromically (or HOMO-LUMO energy gap 
decreases) as their sizes increase.1, 3, 6, 7 Such highly size-dependent properties 
have allowed Au NPs to be employed in a wide variety of applications such as 
electronics, water remediation, catalysis, biological sensors and imaging, drug 
delivery, and cancer therapy.1-3, 8 
Since early 1990s, the most common synthesis of thiolated Au NPs involves 
two major steps: (1) the reduction of Au(III) to Au(I) by thiols and (2) the 
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reduction of Au(I) complexes to thiolated Au NPs with a strong reducing agent 
(e.g., NaBH4).
9, 10 As the core size of the NPs is critical to their properties and 
applications, many studies have explored the synthetic parameters that could be 
manipulated to control the size of the resultant Au NPs. Several studies found a 
strong correlation between the thiol-to-Au ratio and the NP size.  For instance, 
in a study by Hussain et al.11, for the formation of near-monodisperse Au NPs 
in the 1–4 nm size range, the particle sizes were controlled precisely by the 
thiol-to-Au ratio used for the syntheses.  Particle sizes decreased as the thiol-to-
Au ratio increased.  This observation that higher thiol-to-Au ratios lead to 
smaller particle diameters was also confirmed in studies by Chen et al. and 
Shimmin et al.12, 13 
Shimmin et al. proposes two mechanisms to explain this observation: the 
steric hindrance effect and the nucleation enhancement effect. For the steric 
hindrance effect, at high thiol-to-Au ratios, there is a high concentration of free 
thiols which increases the rate of formation of the monolayer thiol protecting 
layer.  This monolayer of thiol protects the Au core and stabilizes the Au NP, 
thereby preventing gold atoms from further aggregating or adding to the core.  
Hence, further growth of the Au NP is prevented and smaller Au NPs are 
formed.  As for the nucleation enhancement effect, high thiol-to-Au ratios (i.e. 
high concentrations of free thiols) lead to enhanced particle nucleation, and the 
Au in the solution is rapidly exhausted. This causes Au atoms to be distributed 
over a large number of smaller NPs rather than aggregated to form larger NPs.13 
Both of the mechanisms are based on the structural model of monolayer-thiol-
protected Au NPs where the gold core is stabilized by a monolayer of thiolate 
ligands (Scheme 6.1a). With this monolayer model, it is expected that particle 
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size is largely dependent on the concentration of free thiols or thiolates, which 
in turn is dependent on the thiol-to-Au ratio. However, recent studies on the 
structure of Au NCs have revealed that the gold cores of NCs are stabilized by 
a shell of Au(I)–thiolate complex motifs rather than a monolayer of thiols.3, 14-
17 These Au(I)–thiolate complex motifs are likely the remnants of Au(I)–thiolate 
complex precursors and therefore are closely related to Au(I)–thiolate complex 
precursors.18 On the basis of this new structural model of small Au NPs, we 
hypothesize that the size and type of Au(I)–thiolate complex precursors could 




Scheme 6.1 Comparison of the structural models of (a) monolayer thiol 
protected Au NPs and (b) Au(I)–thiolate complex motif stabilized Au NPs 
suggests that the Au(I)–thiolate complex precursors could be the key to 
controlling the size of small thiolated Au NPs. 
 
Recent studies on the structures of thiolated Au NCs also suggest that larger 
NCs have more monomeric the Au(I)–thiolate complex motifs (or [Au(SR)2]–). 
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For examples, Au25 clusters consist of an Au13 core capped by six dimeric staple 
motifs ([Au2SR3]
–) and no monomeric motifs ([Au(SR)2]
−), whereas the 
structure of Au144(SR)60 consists of purely monomeric motifs (Table 6.1).
3, 16, 
19-21 This is due to the greater curvature of the structure of smaller Au NPs which 
require longer staple motifs to align to their structure. Larger Au NPs which 
have less curvature require straight monomeric staple motifs.14, 17, 19, 20, 22-26 The 
size distributions of the structural motifs are summarized for three structurally 
determined thiolated Au NC species. Therefore, dominance of monomeric 
Au(I)–thiolate complexes in the precursors could lead to the formation of large 
Au NCs or NPs. For water-soluble ligands that contains at least one carboxyl 
group, the size of Au(I)–thiolate complex precursors can be controlled by 
varying the thiol-to-Au ratio at high pH (e.g., pH 12.6), and monomeric Au(I)–
thiolate complex precursors are synthesized using high thiol-to-Au ratios as 
more thiol can facilitate the decomposition of polymeric Au(I)–thiolate 
complexes: –[Au–SR]n– + n −SR → n [Au(SR)2]−.27, 28 Thus, high thiol-to-Au 
ratios would lead to the formation of relatively large Au NCs or NPs contrary 
to the established trend in which higher thiol-to-Au ratios result in the formation 
of smaller Au NPs. 
 
Table 6.1 Comparison of Au NPs and their stabilizing Au(I)–thiolate 
complex motifs. 
 [Au25(SR)18]
− Au38(SR)24 Au102(SR)44 Au144(SR)60 
[Au(SR)2]
− 0 3 19 30 
[Au2(SR)3]




6.2 Experimental section 
Chemicals. Ultrapure Millipore water (18.2 MΩ) was used throughout the 
experiment. Hydrogen tetrachloroaurate (III) hydrate (HAuCl4·3H2O) from 
Alfa Aesar; sodium borohydride (NaBH4), 3-mercaptobenzoic acid (m-MBA), 
and 3-mercaptopropionic acid (3-MPA) from Sigma-Aldrich; sodium 
hydroxide (NaOH) from Merck; were used as received without further 
purification. 
Syntheses of particles using different thiol-to-gold ratios. In a typical 
synthesis using a thiol-to-Au ratio of 1:8, aqueous solutions of m-MBA (50 mM 
in 150 mM NaOH, 0.0125 mL) followed by HAuCl4 (39.93 mM, 0.125 mL) 
were added to ultrapure water (~4.462 mL) under stirring (500 rpm) at 25 oC. 
The pH of the solution was brought to approximately 12.6, and the reaction was 
allowed to stand for 30 minutes before the addition of NaBH4 (100 mM, 0.100 
mL). The total volume of the solution after addition of all chemicals was 5mL. 
This procedure was repeated for other thiol-to-Au ratios by varying the amount 
of m-MBA added. 
Material characterization. UV–vis absorption spectra were acquired on a 
Shimadzu UV-1800 spectrometer using standard quartz cuvettes. Transmission 
electron microscopy (TEM) images of the synthesized NPs/NCs were taken on 
a JEOL JEM 2010 microscope operating at 200 kV. Polyacrylamide gel-
electrophoresis (PAGE) experiments were carried out using a vertical 
electrophoresis cell (Mini-PROTEAN Tetra Cell, Bio-Rad) that employs 
discontinuous gels with a size of 1.0 × 83 × 73 mm. The resolving and stacking 
gel were prepared by 30 wt% and 3 wt% of acrylamide monomers 
[acrylamide/bis-(acrylamide) = 29:1], respectively. For analytical gels (10-
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well), sample solutions (12 μL of Au NPs/NCs with 2 μL of 60 vol% glycerol) 
were loaded into the wells of the stacking gel. The eluting buffer consisted of 
1.5 mM Tris-HCl (pH 8.8) diluted to ten times. The electrophoresis was allowed 
to run for about 1.5 h at a fixed current of 15 mA. 
 
 
6.3 Results and discussion 
6.3.1 Controlling the Au(I)–thiolate complex precursor types and sizes 
by tuning thiol-to-Au ratio 
To test our hypothesis that higher thiol-to-Au ratios could lead to the formation 
of larger Au NPs by making monomeric Au(I)–thiolate complex [Au(SR)2]− the 
dominant species among the precursors, thiol-to-Au ratios including 1:8, 1:3, 
1:1, 2:1, 3:1, 5:1 and 8:1 were used for the synthesis of thiolated Au NPs while 
the concentration of Au was kept constant. The simple thiol m-MBA, which has 
one carboxylic group, was used as the model thiol. First, we show the control 
over the sizes and types of the Au(I) complex precursors by controlling the thiol-
to-Au ratio at the synthesis pH (pH 12.6). For low thiol-to-Au ratios (1:8 and 
1:3), non-thiolate-coordinated Au(I) complexes, such as [AuCl2]
– and [AuOH2]
–
, are expected to form as the insufficient thiols are quickly exhausted. These 
non-thiolate-coordinated Au(I) complexes does not show much absorption 
above 350 nm (Figure 6.1a). For intermediate thiol-to-Au ratios (1:1 and 2:1), 
oligomeric or polymeric Au(I)–thiolate complex precursors are expected to 
form (–[AuSR]n–). These relatively long complexes show significant absorption 
above 350 nm (Figure 6.1b). 8, 18, 29, 30 For high thiol-to-Au ratios (3:1, 5:1 and 
8:1), excess thiol ligands could break down oligomeric or polymeric Au(I)–
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thiolate complex precursors into monomeric Au(I)–thiolate complex [AuSR2] – 
as illustrated by the following equation:  (–[Au(SR)]n–  + n SR– (or excess) → 
[RS–Au–SR]– ).31 The absorption of the monomeric or short complexes blue 
shifts relative to that of oligomeric complexes (Figure 6.1c) as reported by 
Brinas et al.8 It is worth mention that m-MBA has an absorption peak at ~330 
nm, which become obvious in the spectra of samples with high thiol-to-Au 
ratios. The UV–vis absorption spectra (Figure 6.1) confirms that by controlling 




Figure 6.1 UV–vis spectra of precursors: (a) low thiol-to-Au ratios (1:8 and 
1:3), (b) intermediate thiol-to-Au ratios (1:1 and 2:1), (c) high thiol-to-Au ratios 
(3:1, 5:1 and 8:1). 
 
6.3.1 Synthesis of monodisperse ~2 nm nanoparticles with high thiol-
to-Au ratio 
The syntheses using various thiol-to-Au ratios were carried out under well-
controlled conditions including a fixed high pH (which slows down the 
hydrolysis of NaBH4), an excess of NaBH4 (two equiv of Au), and a long 
reaction time (72 h). Figure 6.2a–c shows the UV–vis absorption spectra of the 
final products. In Figure 6.2a, the products of low thiol-to-Au ratios (1:8 and 
1:3) appear purple under room light and show strong surface plasmon resonance 
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(SPR) peaks at ~550 nm, indicating the formation of large Au nanocrystals.2, 5 
In Figure 6.2b, the products of intermediate thiol-to-Au ratios (1:1 and 2:1) 
appear yellow-to-brown under room light and show featureless spectra without 
SPR peak and are thus likely to be Au NCs instead of Au NPs.2 Surprisingly, 
the products of high thiol-to-Au ratios (3:1, 5:1 and 8:1) appear reddish under 
room light and show well-defined SPR peak at ~510 nm in their absorption 
spectra, suggesting these are small Au nanocrystals.2, 5 The U-shape size trend 
from large nanocrystals to nanoclusters to small nanocrystals as the thiol-to-Au 
ratios increase from 1:8 to 8:1 was confirmed by the PAGE analysis of the final 
products (Figure 6.2d). While the nanoparticles synthesized using low thiol-to-
Au ratios were too large to enter the resolving gel, the nanoparticles synthesized 
from intermediate thiol-to-Au ratios were indeed nanoclusters and moved 
farthest in the resolving gel. Particles synthesized using high thiol-to-Au ratios 
were able to enter the resolving gel but moved much slower than the 






Figure 6.2 UV–vis spectra for all samples with photos inset: (a) low thiol-to-Au 
ratios (1:8 and 1:3), (b) intermediate thiol-to-Au ratios (1:1 and 2:1), and (c) high thiol-
to-Au ratios (3:1, 5:1 and 8:1). (d) PAGE analysis of all samples. (e) Graph of average 
particle diameter versus thiol-to-Au ratio (with error bars) from TEM results. (f) TEM 
micrographs with particles size histograms: thiol-to-Au ratio = (i) 1:8, (ii) 1:3, (iii) 1:1, 
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The sizes of the final products were confirmed by TEM analysis. Figures 
6.2f(i–vii) give an indication of the sizes of the particles in the different samples 
prepared using different thiol-to-Au ratios. As the thiol-to-Au ratio increases 
from 1:8 to 2:1, the particle size decreases from an average of 6.42 nm to 1.32 
nm. However, further increasing the thiol-to-Au ratio to the high ratios (3:1 to 
8:1), ~2 nm nanocrystals were formed. The overall trend of how particle size 
varies with thiol-to-Au ratio is shown in figure 6.2e, which clearly indicates an 
initial decrease followed by a subsequent increase in particle diameter as thiol-
to-Au ratio increases. Besides the U-shape size trend, both PAGE and TEM 
results suggest that the ~2 nm nanocrystals synthesized using high thiol-to-Au 
ratio are highly monodisperse. These nanocrystals are able to self-assemble into 
three-dimensional structures, which suggests that their size variations are small. 
To understand the formation mechanisms of the nanoparticles, time 
evolution of UV–vis spectrum of the reaction mixture of each thiol-to-Au ratio 
was measured (Figure 6.3). For the reaction mixture with low thiol-to-Au ratios, 
the rate of synthesis was very fast; most large Au NPs were formed within 30 
min after the addition of NaBH4 (Figure 6.3a and b), which is expected because 
non-thiolate-coordinated Au(I) complexes are highly reactive towards NaBH4 
reduction. The rates of formation of nanoclusters in the reaction mixtures with 
intermediate thiol-to-Au ratios were also relatively fast, the UV–vis absorption 
spectra of these reaction mixture became stationary within 6 h (Figure 6.3c and 
d). The fast formation of the nanoclusters could be attributed to the oligomeric 
Au(I)–thiolate complex precursors, which are highly reactive toward 
reduction.29 In contrast, the absorption peaks the reaction mixture with high 
thiol-to-Au ratios grew slowly and became stationary only after 24 h (Figure 
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6.3e–g). Their slower reaction rate is because their precursors are mainly 
monomeric Au(I)–thiolate complex precursors, which are much less reactive 
toward reduction than oligomeric Au(I)–thiolate.29 
 
 
Figure 6.3 UV–vis spectra time evolution for all samples: (a) 1:8, (b) 1:3, 
(c) 1:1, (d) 2:1, (e) 3:1, (f) 5:1, and (g) 8:1. 
 
On the basis of the precursor sizes and reaction kinetics of the reaction 
mixtures with different thiol-to-Au ratios (Scheme 6.2), we are able to propose 
a kinetically and thermodynamically controlled formation mechanisms for the 
~2 nm thiolated Au nanocrystals. The formation of the nanocrystals starts with 
the reduction of monomeric Au(I)–thiolate complex precursor [Au(SR)2]− in the 
reaction solutions to form Au(0) atoms. The high stability of [Au(SR)2]
− against 
the reduction results in the slow growth of Au(0) cores, which allows sufficient 
time for the cores to be capped by [Au(SR)2]
− motifs. However, when the Au(0) 
core is too small, the [Au(SR)2]
− motifs cannot provide adequate protection for 
the highly curved surface of the core. Thus, the Au(0) core will continue to grow 
slowly until it reaches a size that is sufficiently large to support flat facets. Thus, 
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all particles eventually reached to the same size and structure. If the reduction 
rate is too fast, the growth of Au(0) cores will be much faster than the rate at 
which [Au(SR)2]
− attached to the cores, which will result in the formation of 
large and polydisperse nanocrystals. If the precursor contains more oligomeric 








In conclusion, we have successfully demonstrated the synthesis of highly 
monodisperse ~2 nm water-soluble thiolated Au nanocrystals using high thiol-
to-Au ratio that can ensure the precursor contains high proportion of monomeric 
Au(I)–thiolate complex, and we have also proposed a kinetically and 
thermodynamically controlled formation mechanism for this synthesis. This 
study highlights the significance of Au(I)–thiolate complex precursors in the 
formation of Au NPs/NCs and opens up a new understanding of thiol-to-Au 



































lead to synthesis of highly monodisperse and small noble metal nanocrystals 
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CHAPTER 7    
Ultrasmall Au10−12(SG)10−12 Nanomolecules for High Tumor 
Specificity and Cancer Radiotherapy 
7.1 Introduction 
Radiotherapy has been considered as part of the treatment regime following 
tumor surgical removal. It has high efficacy as up to 50% patients are treated 
with radiotherapy during their battle against cancer.1, 2 Nevertheless, high 
energy radiation during the treatment not only kills tumor cells but also 
obliterates healthy cells along with them, leading to unavoidable damage to 
normal tissues. Localizing and controlling the radiation dose can maximize 
tumor eradication and minimize side effects. The use of radiosensitizers to 
increase the local treatment efficacy under a relatively low and safe radiation 
dose is the most promising solution to address this challenge. Conventional drug 
based radiosensitizers like misonidazole while are efficacious at the site of the 
tumor do not have any targeting capabilities and rely heavily on precise 
localization of the drug to the tumor cells.3, 4 Sometimes for very small tumors 
with dispersed distribution within a tissue, it becomes impossible to avoid the 
interspersed normal tissues while only affecting the tumor cells. An ideal 
radiosensitizer should have high radiotherapy enhancement, good tumor 
targeting capability (at both tissue and cellular level), good biocompatibility (or 
low toxicity), and efficient renal clearance to avoid potential short- and long-
term detrimental effects on the patient. No radiosensitizers in the current 
development can meet all these requirements. 
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To address these unresolved challenges, here we report a new class of 
radiosensitizers – several gold (Au) atoms embedded inside a peptide shell 
comprising of a naturally-occurring peptide such as glutathione or GSH. As 
illustrated in Figure 7.1, the as-designed nanomolecule has a well-defined 
molecular formula of Au10−12(SG)10−12, and can be classified as GSH-Au 
nanomolecule or nanocluster.5-7 The GSH-covered surface of the nanomolecule 
has similar physicochemical and physiological properties as that of a 
polypeptide comprising of several GSH molecules, and this class of materials 
have been shown to have good biocompatibility in biological systems.8, 9 The 
GSH shell also makes good tumor deposition of the GSH-Au nanomolecules 
possible by affecting their in vivo pharmacokinetics. The ultrasmall size and the 
peptide shell may help the GSH-Au nanomolecules escape the reticulo-
endothelial system (RES), thus improving their deposition in tumor. Moreover, 
the high ratio of GSH in the as-designed GSH-Au nanomolecules (or highly 
exposed GSH on the nanomolecule surface) could possibly activate the GSH 
transporters inside the body, which could facilitate the uptake of GSH-Au 









The Au atoms in the GSH-Au nanomolecules could be used as 
radiosensitizers to enhance the therapeutic efficiency of radiotherapy. Among 
several high-Z materials recently developed as radiosensitizers,10-12 including 
iodine (Z = 53), and gadolinium (Z = 64), gold is unmatched in terms of 
enhancement efficiency because of its large atomic number of 79. The several 
Au atoms embedded inside a GSH shell could further improve the therapeutic 
efficiency by providing a locally high Au concentration in tumor with potential 
synergistic effects. The radiotherapy enhancement comes from the direct 
interaction between Au and radiation, where, upon receiving high-energy X-ray 
or gamma-ray radiation, the GSH-Au nanomolecules become a new source of 
radiation and emit high energy through scattered photons, photoelectrons, 
Compton electrons, Auger electrons, and electron-positron pairs, causing 
radiochemicals (free radicals and ionizations) within the cells that can damage 
and kill cancer cells.13, 14  
Taken together, the GSH-Au nanomolecules inherit attractive features of 
both gold atoms and naturally occurring molecules, which could prolong their 
blood circulation and improve their tumor deposition. The ultrasmall size of 
GSH-Au nanomolecules may also make high renal clearance possible after 
treatment, which could minimize their potential side effects due to the 
accumulation of Au in body. This feature could not be replicated by most of 
other inorganic-based theranostic agents, such as metal nanoparticles,15-18 
carbon nanotubes,19, 20 and semiconductor quantum dots,21 because they have 
relatively large hydrodynamic diameters (HDs, typically >10 nm), which are 
above the threshold of kidney filtration (~5.5 nm).22 The metabolizable feature 
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7.2 Experimental section 
Synthesis of Au10–12(SG)10–12 Nanomolecules. The synthesis of Au10–12(SG)10–
12 nanomolecules followed a reported method.
23 In a typical synthesis, aqueous 
solutions of HAuCl4 (20 mM, 0.5 mL) and GSH (100 mM, 0.2 mL) were mixed 
with 4.3 mL of ultrapure water under rigorous stirring (500 rpm) at 25 °C for 5 
min. A precipitate was formed and was then dissolved by adjusting pH to ~7.0 
with NaOH (0.5 M). The solution was incubated at 40 °C. After 2 h, the product, 
Au10–12(SG)10–12 nanomolecule, was collected. 
Characterizations of Au10–12(SG)10–12 Nanomolecules. The UV-vis 
absorption spectrum was recorded in aqueous solutions at 25 °C on a 
spectrophotometer (UV-1800, Shimadzu). The electrospray ionization mass 
spectrometry (ESI-MS) was carried out with a Bruker MicroTOF-Q ESI time-
of-flight system operating in the negative ion mode (sample injection rate 120 
μL·min−1; capillary voltage 3 kV; nebulizer 1.5 bar; dry gas 4 L·min−1 at 160 
°C). GSH-Au nanomolecules was purified for ESI-MS measurement according 
to the following procedure: 200 µL of as-synthesized Au10–12(SG)10–12  
nanomolecules was first precipitated by mixing with acetic acid (20 µL) and 
ethanol (1.3 mL); the pellet was then washed with Dimethylformamide and 
redissolved in water (400 µL). 
In vivo Biodistribution. Forty-eight mice were purchased, maintained, and 
handled using protocols approved by the Institute of Radiation Medicine, 
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Chinese Academy of Medical Sciences (CAMS). The U14 tumor models were 
generated by subcutaneously injecting 2 × 106 cells (in 50 μL of PBS) into the 
right shoulders of male nude mice. Au10–12(SG)10–12 nanomolecules (3 mM per 
Au atoms, 0.2 mL) was injected through the intraperitoneal routes into mice. 
The mice were sacrificed at 0.5, 1, 2, 6, 12, 24, 48, and 72 h post injection (p.i.). 
The tumor and main organs including the liver, kidney, spleen, heart, lung, and 
brain were collected and digested using a microwave system CEM Mars 5 
(CEM, Kamp Lintfort, Germany). Their Au contents were then measured using 
inductively coupled plasma mass spectrometry (ICP-MS, Agilent 7500 CE, 
Agilent Technologies, Waldbronn, Germany). 
In vivo Imaging. Eighteen mice were purchased, maintained, and handled 
using protocols approved by the Institute of Radiation Medicine, CAMS. The 
U14 tumor models were generated by subcutaneously injecting 2 × 106 cells (in 
50 μL of PBS) into the right shoulders of male nude mice. The mice were 
anesthetized by chloral hydrate before the experiment. For CT imaging, Au10–
12(SG)10–12 nanomolecules (40 mM per Au atoms, 0.2 mL) was injected through 
the intraperitoneal routes into the mice. Each mouse was imaged on a small-
animal scanner (microPET/CT, Inveon, Siemens) and was exposed to a 10-min 
CT scan. The images were reconstructed using the filtered back-projection 
algorithm with CT-based photon-attenuation correction. The CT data were 
analyzed for regions of interest including the tumor, bladder, and spleen. 
In vivo Radiation Therapy. Forty-eight mice were purchased, maintained, 
and handled using protocols approved by the Institute of Radiation Medicine, 
CAMS. The U14 tumor models were generated by subcutaneously injecting 2 
× 106 cells (in 50 μL of PBS) into the right shoulder of BALB/c mice. The mice 
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were intraperitoneally injected with Au10–12(SG)10–12 nanomolecules when the 
tumor volume reached 100–120 mm3 (7 days after tumor inoculation). For each 
treatment, Au10–12(SG)10–12 nanomolecules (10 mM per Au atoms, ~0.2 mL)) 
were intraperitoneally injected at a dose of 20 mg/kg in the mice. The control 
group were intraperitoneally injected with 200 μL of saline for each mouse. The 
mice were subsequently irradiated by 5 Gy gamma rays from 137Cs (photon 
energy 662 keV) with an activity of 3600 Ci p.i.. Forty-eight mice were assigned 
to the following six groups (eight mice per group): control, Au10–12(SG)10–12 
only, radiation only, and Au10–12(SG)10–12 + radiation. Every group includes four 
male and four female mice in order to monitor the gender difference. The tumor 
sizes were measured every two or three days and calculated according to this 
equation: tumor volume = (tumor length) × (tumor width)2 / 2. 
In vivo Toxicity. Mice were purchased, maintained, and handled using 
protocols approved by the Institute of Radiation Medicine, CAMS. The mice 
treated with saline (control) and Au10–12(SG)10–12 nanomolecules only were 
weighed and assessed for behavioral changes. All mice were sacrificed at 20 
days p.i., and their blood and organs were collected for hematology, 
biochemistry and pathological investigation from therapy mice. The blood was 
drawn for hematology analysis (potassium EDTA collection tube) and serum 
biochemistry analysis (lithium heparin collection tube) using a standard 
saphenous vein blood collection technique. During necropsy, the liver, kidney, 
spleen, heart, lung, brain, genitals, tumor, and thyroid were collected and 
weighed. Major organs including the liver, spleen, and kidney from these mice 
were then fixed in 4% neutral buffered formalin, processed into paraffin, and 
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stained with hematoxylin and eosin (H&E). The pathology data were collected 
with a digital light microscope. 
 
 
7.3 Results and discussion 
The preparation of GSH-Au nanomolecules is simple.23 In a typical synthesis, 
aqueous solutions of GSH and HAuCl4 (GSH-to-Au ratio = 2:1) were first 
mixed at 25 °C for 5 min, followed by the addition of NaOH to bring the pH of 
the mixture to ∼7.0. The mixture was then incubated at 40 °C for ∼2 h, leading 
to the formation of the GSH-Au nanomolecules. The above formation process 
involved two steps. The first step was the reduction of Au(III) by GSH to form 
insoluble aggregates of polymeric Au(I)−SG complexes, and the second step 
was initiated by the addition of NaOH, which caused the dissociation of the 
polymeric complexes to form soluble oligomeric Au(I)−SG complexes or GSH-
Au nanomolecules. The resulting reaction mixture was clear and colorless. The 
as-synthesized GSH-Au nanomolecules showed two distinct peaks at 330 and 
375 nm (Figure 7.2a), which matched nicely with Au10−12(SG)10−12 
nanomolecules reported by Negishi et al.24 The formation of Au10−12(SG)10−12 
nanomolecules in the product was confirmed by its electrospray ionization mass 





Figure 7.2 (a) UV-vis absorption and (b-d) ESI mass spectrum of the as-
synthesized GSH-Au nanomolecules, indicating the formation of 
Au10−12(SG)10−12 nanomolecules in the product. The series of isotope 
distributions shown in (c) are resulted from the replacement of the carboxyl H+ 
of GSH by Na+ or K+. The red line in (d) is the simulated isotope distribution of 
[Au10(SG)10−3H+]3−. 
 
Au10−12(SG)10−12 nanomolecules showed ultrahigh uptake in tumor 
compared to normal tissues; such targeting capability is essential for minimizing 
damage to normal tissues during the radiation treatment. The tumor uptake of 
Au10−12(SG)10−12 nanomolecules was first investigated by analyzing the 
standardized uptake values (SUVs) of Au in the tumor tissue at different time 
points post injection (p.i.). SUV is defined as (weight of Au/weight of tissue 
sample)/(weight of Au injected into animal/total body weight). The mice were 
intraperitoneally injected with Au10−12(SG)10−12 nanomolecules, and the 
postmortem tissue samples were treated and analyzed (Supplementary 
Information). As shown in Figure 7.3a, the accumulation of Au in the tumor 
increased sharply from 6 to 10 h p.i., and gradually reached a maximum at 24 h 
p.i with a SUV of 10.86, which could be retained up to 48 h p.i. The tumor 
uptake of Au10−12(SG)10−12 nanomolecules at 24 h p.i. is about an order of 
magnitude higher than those of tiopronin-protected Au nanoparticles (~2 nm) 
and PEG-coated Au nanorods (~20 nm).25, 26 The ultrahigh uptake of 






























structural and size features.27-29 The first feature is their ultrasmall HD, which 
is around 2 nm. Particles in this size regime may benefit most from the enhanced 
permeability and retention (EPR)30 and nanomaterials-induced endothelial cell 
leakiness (NanoEL) effects.31 The second feature is their high GSH-to-Au ratio, 
which is 1:1. A high content of GSH in the as-designed molecules could largely 
lead them to behave like a polypeptide consisting of GSH molecules, which 
could help the nanomolecules escape the RES absorption, as well as may 
activate the GSH transporters on cell surface to further improve the uptake of 
Au10−12(SG)10−12 nanomolecules in tumor cells. 
 
 
Figure 7.3 (a) Standard uptake values (SUV) of Au10−12(SG)10−12 
nanomolecules in tumor at different time points p.i. (b) Pharmacokinetics of 
Au10−12(SG)10−12 nanomolecules in mice from 0 to 72 h p.i.  
 
To further understand the reason for the ultrahigh tumor uptake of 
Au10−12(SG)10−12 nanomolecules, we studied the pharmacokinetics of 
intraperitoneally injected Au10−12(SG)10−12 nanomolecules in mice. As shown in 
Figure 7.3b, it is obvious that Au10−12(SG)10−12 nanomolecules followed a two-
compartment pharmacokinetics. It has a distribution half-life (first phase t1/2α) 
of ~2.4 h, which is slightly longer than the previously reported Au25(SG)18 
nanomolecules and other small Au particles.9, 32 On the other hand, Figure 7.3b 























also suggests that Au10−12(SG)10−12 nanomolecules have a blood-elimination 
half-life (second phase t1/2β) of ~22 h. Moreover, it was found that, even after 
24 h p.i., the blood concentration of Au10−12(SG)10−12 nanomolecules was still 
above 4.91 SUV. This value is ~20 times higher than that of the Au25(SG)18 
nanomolecules, and higher than reported small Au NPs.9, 32 Taken together, the 
combination of both the long half-lives and the long-lasting high blood 
concentration could be the major contributor for the ultrahigh tumor uptake of 
Au10−12(SG)10−12 nanomolecules. 
To further understand the in vivo behavior of Au10−12(SG)10−12 
nanomolecules, we have studied their biodistribution at 24 h and 23 days p.i. As 
shown in Figure 7.4, at 24 h p.i., the concentration of Au10−12(SG)10−12 
nanomolecules in tumor was much higher than that of all other key organs 
including kidney and liver. For instance, the ratios of the nanomolecule 
concentration in tumor to that in kidney and liver were 1:0.172 and 1:0.0446, 
respectively. Such a high targeting specificity of Au10−12(SG)10−12 
nanomolecules is highly desirable because it can constrain the radiotherapy 
sensitization within the tumors and minimize possible damages to normal 
tissues. The high targeting specificity of Au10−12(SG)10−12 nanomolecules could 
be attributed to their biocompatible surface and ultrasmall size features, which 
help them evade the uptake by the RES organs, such as liver and spleen. On the 
other hand, at 23 days p.i., the nanomolecule concentrations in all the key organs 
and the tumor were dropped below 0.019 SUV, which clearly suggest that 





Figure 7.4 Biodistribution of Au10−12(SG)10−12 at 24 h and 23 days p.i. 
 
To confirm the selective deposition of Au10−12(SG)10−12 nanomolecules in 
tumor, X-ray computed tomography (CT) was used to image the distribution of 
the nanomolecules in body. In vivo X-ray CT imaging is a non-invasive and 
reliable method for tumor imaging.8, 33 The CT signal depends on the 
concentration of Au atoms (from the injected Au10−12(SG)10−12 nanomolecules) 
in tissues, and a CT value of 745 HU that corresponds to 40 mM of Au is suitable 
for in vivo imaging. Au10−12(SG)10−12 nanomolecules (40 mM Au, 0.2 mL) were 
intravenously injected into mice, and three- and two-dimensional X-ray CT 
images were recorded. As shown in Figure 7.5, an obvious tumor uptake was 
clearly seen at the tumor site (indicated by arrows) at 6 h p.i. The corresponding 
CT value was determined to be 326 HU, which is significantly higher than that 
of the muscle tissue (207 HU). In addition, a clear boundary between the tumor 
and normal tissues was observed. Taken together, the X-ray CT images provide 
strong evidences on the above discussed biodistribution data of Au10−12(SG)10−12 
nanomolecules. 
 
















Figure 7.5 (a) Three- and (b) two-dimensional small animal X-ray CT 
imaging of Au10−12(SG)10−12 at 6 h p.i. 
 
The radiotherapy sensitization efficacy of the GSH-Au nanomolecules were 
tested using U14 tumor bearing nude mice as the animal model. The mice were 
intraperitoneally injected with Au10−12(SG)10−12 nanomolecules (10 mM Au, 0.2 
mL) to a concentration of 20 mg-Au/kg-body. The mice were irradiated under 
137Cs gamma radiation of 3600 Ci at a 5 Gy dose at 24 h p.i. when the tumor 
uptake of Au10−12(SG)10−12 nanomolecules reached the maximum (Figure 7.3a). 
The time-dependent tumor volumes and tumor weights at the time point of 23 
day in the sacrificed mice were measured (Figure 7.6a and b). The tumor volume 
did not show any decrease for mice treated with Au10−12(SG)10−12 only. As 
compared with the control group and mice treated with radiation only, tumor 
volume in mice treated with both Au10−12(SG)10−12 nanomolecules and radiation 
decreased ~65% and ~57%, respectively. Correspondingly, the tumor weight in 
mice treated with both Au10−12(SG)10−12 nanomolecules and radiation decreased 
significantly relative to tumors in the control group, mice treated with 
Au10−12(SG)10−12 only, and mice treated with radiation only. Therefore, the as-
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Figure 7.6 Time-course studies of tumor (a) volumes and (b) weights of 
untreated mice (control), mice treated with Au10−12(SG)10−12 only, mice treated 
with radiation only, and mice treated with both Au10−12(SG)10−12 and radiation. 
Data is analyzed by student’s t-test, and the star denotes significant difference 
from the control group (p < 0.05). 
 
The extent of the radiotherapy sensitization effect strongly depends on the 
tumor uptake of the radiosensitizers. The traditional molecular radiosensitizers 
such as cisplatin can achieve high tumor uptake as well as good radiotherapy 
sensitization. However, the renal clearance of cisplatin was slow, which could 
cause potential kidney toxicity.34, 35 On the other hand, those radiosensitizers 
with relatively large HDs (e.g., >20 nm) were not able to evade RES clearance, 
and they may also cause potential liver toxicity.36 However, the as-designed 
Au10−12(SG)10−12 nanomolecules in this study feature with efficient tumor 
uptake, high targeting specificity, and efficient renal clearance. As an attractive 
potential radiosensitizer, the toxicity response of Au10−12(SG)10−12 
nanomolecules, including blood chemistry, biochemistry and pathology, were 
further examined. No loss of the body weight or abnormal organ indices (data 
not shown) were observed for mice treated with Au10−12(SG)10−12 






































































nanomolecules at a dose of 20 mg-Au/kg-body, which was used for 
radiotherapy sensitization. The typical chemistry and biochemistry data (data 
not shown) showed that platelets (PLT), hematocrit (HCT), and blood urea 
nitrogen (BUN) were decreased in mice treated with Au10−12(SG)10−12 
nanomolecules, but they were recovered at 23 days p.i. No obvious damage to 
key organs including the liver, spleen, and kidney were observed in mice treated 
with Au10−12(SG)10−12 nanomolecules (data not shown). Therefore, 
Au10−12(SG)10−12 nanomolecules can be considered safe for the radiotherapy 




In summary, the ultrasmall size of the Au10−12(SG)10−12 nanomolecules could 
increase the tumor uptake and targeting specificity via the improved EPR effect, 
while the highly exposed biocompatible GSH shell on the nanomolecule surface 
could further contribute to their tumor uptake by allowing the nanomolecules to 
escape the RES absorption and activating the transporter on cell surface. The 
ultrahigh tumor uptake, targeting specificity, and efficient renal clearance of 
ultrasmall Au10−12(SG)10−12 nanomolecules with highly exposed GSH ligands 
allows them to be ideal radiotherapy sensitizers that can enhance the safety and 
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CHAPTER 8    
CONCLUSIONS AND RECOMMENDATINS 
8.1 Conclusions 
The main objective of this thesis project is to explore bio-integrated synthesis 
of noble metal NCs for biomedical applications, and we chose thiolated Au NCs 
to be used for radiotherapy sensitization as the model system to explore. To 
achieve the ideal bio-integrated synthesis, fundamental understanding about the 
properties of thiolated Au NCs and effective methods to precisely controlling 
the properties of the NCs are necessary. For applying thiolated Au NCs as 
radiosensitizers, beside biocompatibility and renal clearability, two of the most 
important properties to control are the PL and the size of the NCs. However, 
there is a lack of synthesis methods for highly luminescent or relatively large 
(>29 Au atoms) monodisperse water-soluble thiolated Au NCs because the lack 
of understanding about the PL properties and the formation mechanisms of the 
NCs. Thus, this thesis project focuses on (1) understanding the fundamental 
issues of the PL of thiolated Au NCs and developing new synthetic strategies 
for highly luminescent thiolated Au NCs; (2) understanding the formation 
mechanism of thiolated Au NCs and developing syntheses for relatively large 
monodisperse NCs; and (3) understanding the in vivo behavior (e.g., 
pharmacokinetics and biodistribution) and radiosensitizing effects of thiolated 
Au NCs obtained from bio-integrated synthesis. The major findings of this 
thesis project are listed below: 
First, we discovered an interesting property of oligomeric Au(I)–thiolate 
complexes: strong luminescence emission by the mechanism of aggregation-
induced emission (AIE). The AIE property of the complexes was then used to 
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develop a simple one-pot synthesis of highly luminescent Au–thiolate NCs with 
a quantum yield of 15%. Our key strategy was to induce the controlled 
aggregation of Au(I)–thiolate complexes on in situ generated Au(0) cores to 
form Au(0)@Au(I)–thiolate core–shell NCs where strong luminescence was 
generated by the AIE of Au(I)–thiolate complexes on the NC surface. We were 
able to extend the synthetic strategy to other thiolate ligands with added 
functionalities (in the form of custom-designed peptides). The discovery (e.g., 
identifying the source of emission and the size effect in luminescence) in this 
study can contribute significantly to better understanding of the PL of the 
thiolated Au NCs. The “green” and efficient synthesis methods are ideal for bio-
integrated synthesis. (Chapter 3) 
Second, we studied the PL of thiolated Au NCs synthesized from the most 
common “modified” Brust method. We discovered that the major part of 
emission of both Au(I)–thiolate complexes and thiolated Au NCs is in near-IR 
regime. By comparing the PL spectra of thiolated Au NCs with Au(I)–thiolate 
complexes, we concluded that the emission source of the NCs the Au(I)–thiolate 
complex motifs on the NC surface, and the emission energies depends on the 
length of the motifs. The PLE spectra of the thiolated Au NCs suggests that their 
excitation origin include at least LMCT and the energy transfer from excited 
cores to the surface motifs. The metallic Au cores do not affect the emission 
energies of the NCs, but it can significant enhance the PL intensity of the 
complex motifs by restricting their intramolecular motion. Such understanding 
could lead to the development of new synthetic approaches for highly 
luminescent thiolated Au NCs with tunable near-IR emission, and application 
of these NCs as near-IR bioimaging probes. (Chapter 4) 
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Third, to study the growth mechanism of thiolate Au NCs, we monitored the 
entire transformation from Au(I) complex precursors to the magic [Au25(SR)18]
– 
using UV–vis spectroscopy and ESI-MS, enabled by the mild CO reduction. 
Au(I)–thiolate complex precursors (including chloride-containing ones) and 
stable NC intermediates have been clearly identified. On the basis of the time 
evolution of those species, we were able to propose a reduction-growth 
mechanism of the kinetically controlled NC formation in the fast Stage I and 
inter-cluster conversion pathways in the subsequent, thermodynamically 
controlled size-focusing to [Au25(SR)18]
– (Stage II). These results represent an 
important step forward toward understating the growth mechanism of thiolated 
Au NCs including precursor reduction, NC growth, and NC inter-conversion, 
which can facilitate the development of synthetic strategies for new NCs. 
(Chapter 5) 
Fourth, on the basis of our understanding of the growth mechanism of 
thiolated Au NCs, we successfully developed a new synthetic approach of 
highly monodisperse ~2 nm water-soluble thiolated Au nanocrystals using high 
thiol-to-Au ratio that can ensure the precursor contains high proportion of 
monomeric Au(I)–thiolate complex, and we have also proposed a kinetically 
and thermodynamically controlled formation mechanism for this synthesis. This 
study highlights the significance of Au(I)–thiolate complex precursors in the 
formation of Au NPs/NCs and opens up a new understanding of thiol-to-Au 
ratio effects on particle size. Such understanding and synthetic approach could 
lead to synthesis of highly monodisperse and small noble metal nanocrystals 
with different metal and sizes. The synthesis method is also important for bio-
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integrated synthesis of thiolated Au NCs for radiotherapy as it broadens the core 
size range of the NCs up to 2 nm. (Chapter 6) 
Last, we tested the in vivo performance of a biothiol-protected Au NCs 
Au10−12(SG)10−12 from bio-integrated synthesis for radiotherapy sensitization. 
The ultrasmall size of the Au10−12(SG)10−12 nanomolecules could increase the 
tumor uptake and targeting specificity via the improved EPR effect, while the 
highly exposed biocompatible GSH shell on the nanomolecule surface could 
further contribute to their tumor uptake by allowing the nanomolecules to 
escape the RES absorption and activating the transporter on cell surface. The 
ultrahigh tumor uptake, targeting specificity, and efficient renal clearance of 
ultrasmall Au10−12(SG)10−12 nanomolecules with highly exposed GSH ligands 
allows them to be ideal radiotherapy sensitizers that can enhance the safety and 




The understanding of the PL and growth mechanism of thiolated Au NCs and 
the synthetic strategies developed for highly luminescent thiolated Au NCs and 
~2 nm monodisperse thiolated Au nanocrystals from this thesis project could 
contribute significant to the development of bio-integrated synthesis of thiolated 
Au NCs for biomedical applications including radiotherapy sensitization. 
The understanding of the near-IR emission of thiolated Au NCs could start 
a new era of using virtually sizes of thiolated Au NCs as imaging probes for in 
vivo applications as their near-IR (from 650 to 1300 nm) emission are ideal for 
bioimaging.1 Thus, in vivo studies on the near-IR imaging performance of the 
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thiolated Au NCs, such as spatial and temporal resolution for biological 
processes, tissue- and organ-targeting capability, and biocompatibility, are 
recommended. 
The monodisperse ~2 nm water-soluble thiolated Au nanocrystals 
developed in this study are a fascinating new type of nanoparticles. Their size 
are comparable to nanoclusters, but they show properties of large nanocrystals 
such as SPR. Thus, they have the potential to replace larger Au nanocrystals in 
many applications such as chemical and biological sensing because their 
ultrasmall size could allow them to have better biocompatibility, renal 
clearability, and better sensitivity.2, 3 As compared with nanoclusters, these ~2 
nm nanocrystals may have some advantages in in vivo applications, for 
example, their relatively larger size would allow them to have longer residence 
time in blood and better tumor uptake. 
As all thiolated Au NCs have intense near-IR emission and their core sizes 
can now be tuned up to 2 nm. Bio-integrated synthesis of a series of biothiol-
protected Au NPs with different cores may be synthesized for trial as 
radiosensitizers. By further studying the in vivo behavior (e.g., 
biocompatibility, biodistribution, potential off-target effects, and renal 
clearance), near-NIR imaging performance, and radiosensitizing efficacy of 
thiolated Au NPs, and by incorporating existing synthesis strategies, such as 
conjugating active targeting molecules onto the thiolated NCs, better synthesis 
methods can be designed for thiolated Au NCs that are suitable as 
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